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The overall hypothesis of this thesis project was that bleomycin hydrolase (BLMH) has 
biologically specific and unique functions in the central nervous system (CNS).  BLMH is a 
multifaceted papain superfamily cysteine protease that has importance in drug metabolism.  The 
physiological functions of this protease are unknown as are factors regulating its expression.    
Immunohistochemical examination of B6.129Blmhtm1Geh/J null and control animals showed no 
gross abnormalities; however, marked global astrogliosis was observed in the null aged animals.  
To define the role of BLMH in the brain, the behavioral phenotype of hybrid [129S6-
Blmhtm1Geh/J X B6.129 Blmhtm1Geh/J]F1 null and littermate controls was characterized using 
multiple behavioral paradigms.  Deletion of Blmh was found to result in deficits among young 
animals in water maze probe trials.  Retention of target platform location during the probe trials 
requires both learning and memory as well as sensory and locomoter skills.  No overt sensory or 
motor deficits were noted in Blmh null F1 hybrids. The profile of BLMH expression and its 
regulation in the CNS was studied next.  Inducible transcription of BLMH was evaluated in the 
context of a putative role in the processing of MHC I epitopes.  BLMH was found to be 
differentially regulated in microglia and astrocytes.  In microglia, Blmh protein was significantly 
induced by gamma interferon or tumor necrosis factor a, whereas in astrocytes, no change in 
protein expression was observed. Treatment of microglial derived cell lines with both gamma 
interferon and tumor necrosis factor a revealed synergistic effects between the cytokines.  
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BLMH protein induction was accompanied by increased Blmh mRNA.  These results suggest 
that cell specific regulation of BLMH is an important control mechanism for this protease.  
These data also provide further evidence for a targeted immune related biological function for 
BLMH.  It is concluded that BLMH potentially has multiple unique and biologically important 
functions within the brain.     
 v
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 Bleomycin hydrolase (BLMH) is a multifaceted protein that has importance in drug metabolism 
and potentially a role in human disease.  BLMH was discovered as an enzymatic activity that 
metabolically inactivates the chemotherapeutic agent bleomycin (Umezawa et al., 1972).  
Through this action, BLMH attenuates bleomycin toxicity and may influence susceptibility to 
potentially fatal bleomycin induced pulmonary fibrosis.  To date BLMH remains the only known 
mammalian enzyme that metabolizes bleomycin.  Despite this established role, the physiological 
functions of BLMH remain unknown.  BLMH is a member of the papain superfamily of cysteine 
proteases (Sebti et al., 1989; Bromme et al., 1996).  The protease is a highly conserved cytosolic 
aminopeptidase with broad substrate specificity that exhibits maximal activity at neutral pH 
(Enenkel et al., 1993; Chapot-Chartier et al., 1994; Bromme et al., 1996).  The crystal structure 
of BLMH discloses a homohexameric ring barrel enclosing the active sites (Joshua-Tor et al., 
1995; O’Farrell et al., 1999).  Protease activity appears to be regulated by self-  
compartmentalization as well as through restriction and positioning of the substrate within the 
active site by the BLMH C-terminus (Zheng et al., 1998).  Deletion of Blmh in mice reveals that 
the protease possesses specific, non-redundant functions beyond terminal degradation of cellular 
proteins and peptides (Schwartz et al., 1999).  Emerging evidence suggests a role for BLMH in 
dermal integrity and immune function as well as a potential function in the pathogenesis of 
Alzheimer’s disease. 
1 INTRODUCTION 
1.1 Summary 
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Isolated from Streptomyces verticilus, bleomycin is a mixture of glycopeptide congeners that 
differ in their terminal alkylamine groups (Umezawa, 1966).  Clinically, the glycopeptide is used 
as a chemotherapeutic agent for cancers including squamous cell carcinoma, Hodgkin’s and non-
Hodgkin’s lymphoma and testicular tumors (Blum et al., 1973; Loehrer et al., 1995; de Wit et al., 
1997).  The mechanism of action of the agent is principally due to oxidative cleavage of single 
and double stranded DNA.  The cleavage reaction is initiated by a bleomycin-metal-oxygen 
complex that allows abstraction of a hydrogen atom from the DNA substrate and formation of a 
C-4’ radical (Burger et al., 1979; Giloni et al., 1981; Stubbe et al., 1987; Hecht, 2000).  Although 
bleomycin lacks significant myelotoxicity common to many other chemotherapeutics, tumor 
resistance and potentially fatal pulmonary fibrosis limit its clinical utility.  Pulmonary fibrosis 
arises from acute pulmonary injury and inflammation, and is characterized by interstitial 
collagen deposition and compromised pulmonary function (Jules-Elysee and White, 1990). The 
incidence of bleomycin- induced pulmonary fibrosis is estimated at 1-2% and less serious 
pulmonary toxicity manifested by radiographic changes and dyspnea is observed in 
approximately 6-11% of patients (Blum et al., 1973; Williams et al., 1987; O’Sullivan et al., 
2003).  The molecular basis for this untoward effect is not established, and methodology to 
screen patients prior to treatment is unavailable.   Metabolism of bleomycin by BLMH may be 
an important factor in protection against pulmonary toxicity as well as resistance of malignant 
tissue (Umezawa et al., 1972; Lazo and Humphreys, 1983; Sebti et al., 1991; Jani et al., 1992).  
Deamination of the carboxyamide amino group of the N-terminal baminoalanimide of bleomycin 
by BLMH prevents formation of the active complex.  Consequently, deamido bleomycin 
1.2 Bleomycin metabolism and pulmonary fibrosis 
 3 
possesses significantly le ss biological activity and, in mice, does not induce pulmonary fibrosis 
(Umezawa et al., 1974; Huang et al., 1981; Lazo and Humphreys, 1983). 
Animal models of bleomycin- induced pulmonary fibrosis result in comparable pathology 
to that in human patients (Jules-Elysee and White, 1990) and provide a good system for 
exploring the role of BLMH.  In mice, susceptibility to pulmonary fibrosis induced by bleomycin 
is a heritable trait (Ekinoto et al., 1987; Haston et al., 1996).  Bleomycin sensitive C57BL/6 
inbred strain of mice exhibit significantly less Blmh activity in lung, but not kidney or liver, than 
the fibrosis resistant BALB/c mice (Filderman and Lazo, 1991).  In addition, strain sensitivity to 
pulmonary fibrosis is drug specific as shown by the relative resistance of C57BL/6 mice to 
cyclophosphamide- induced fibrosis in comparison to BALB/c mice (Harrison and Lazo, 1988).  
Deletion of murine Blmh by gene targeting results in a greater than ten fold increased mortality 
from equivalent dosages of bleomycin compared to wild type controls (Schwartz et al., 1999).  
Necropsy results reveal loss of normal hematopoetic cells and increased neutrophilic infiltrates in 
medullary regions of bone and superficial mucosal ulceration and hemorrhage in gut.  Non- lethal 
dosages of bleomycin result in increases in lung hydroxyproline, a measure of collagen content, 
in Blmh null, but not wild type mice indicating increased susceptibility to pulmonary fibrosis in 
null animals.  In humans, differences in bleomycin sensitivity are also heritable based on 
frequency of bleomycin induced chromatid breaks in peripheral lymphocytes of healthy 
volunteers (Cloos et al., 1999).  These differences are attributed in part to DNA repair gene X-
ray repair cross-complementing 1 (XRCC 1) and, to a lesser extent, BLMH (Tuimala et al., 
2002).  Polymorphisms in XRCC 2 and xenobiotic metabolizing enzymes glutathione-S-
transferase M1, T1 and N-acetyltransferase-2 do not affect sensitivity.  Collectively, these 
studies support a vital role for BLMH in protecting nonmalignant tissues from the toxic effects 
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of bleomycin and suggest that genetic variability in Blmh may influence susceptibility to 
pulmonary fibrosis.  
 
BLMH orthologs have been cloned from numerous species ranging from bacteria (pep C) to 
yeast (blh 1, gal 6, ycp 1) to mammals including humans (Sebti et al., 1987;  Neviani et al., 1989; 
Kambouris et al., 1992; Chapot-Chartier et al., 1993;  Bromme et al., 1996; Ferrando et al, 1996).  
The protein is remarkably conserved displaying 40% identity between yeast and human BLMH, 
and over 90% identity among mammalian orthologs (Bromme et al., 1996).  Based on sensitivity 
to inhibitors including iodoacetic acid, N-ethylmaleimide and 1-(L-trans-
epoxysuccinylleucylamino)-4- guanidinobutane (E64), and conservation of active site residues, 
BLMH is classified as a cysteine protease, and a member of the papain superfamily (Sebti et al., 
1989; Bromme et al., 1996).  The MEROPS protease database (Rawlings and Barrett, 2000) 
recognizes seven cysteine protease clans or groups of evolutionarily related families.  The CA 
clan is the largest containing about half the families including the papain like lysosomal 
cathepsins, BLMH and the closely related cytoplasmic Ca2+ dependent calpains (Barrett and 
Rawlings, 2001).  BLMH, cathepsins and calpains share sequence similarity only in the vicinity 
of the active site triad defined by the catalytic cysteine 25, histidine 159 and asparagine 177 
(numbering based on papain) (Polgar et al., 1987; Berti et al., 1995).  Substitution of the yeast 
Blmh Cys102, the putative catalytic cysteine, or His398 abolishes the enzymatic activity 
confirming the essential role of these conserved amino acids (Pei et al., 1996).  These thiol 
1.3 Membership in papain superfamily and evolution 
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proteases also share an ancestral tertiary structure characterized by two large globular domains 
surrounding the active site cleft (Chapman et al., 1997).   
At least 12 unique paralogous cysteine proteases of the papain superfamily exist in 
mammals (Berti et al., 1995).  These are believed to have arisen very early in eukaryote 
evolution through gene duplication (Hughes et al., 1994; Berti et al., 1995).  In prokaryotes, 
BLMH orthologs, which share approximately 38 and 35% identity with the yeast and human 
protease respectively, are found in at least four distinct bacterial species (Neviani et al., 1989; 
Chapot-Chartier et al., 1993; Chapot-Chartier et al., 1994; Klein et al., 1997; Winters et al., 
2000).  These proteases are believed to be part of a complex system tha t functions in the 
acquisition of essential amino acids (Chapot-Chartier et al., 1994; Kunji et al., 1996).  In 
Lactobacillus delbruckii, BLMH like genes, Pep G and orf W, are believe to have arisen by 
duplication of Pep C, the bacterial BLMH ortholog (Kle in et al., 1997).  Curiously, existence of 
prokaryotic forms of BLMH is thought to be due to lateral transfer of the eukaryotic gene (Berti 
et al., 1995).  Acquisition of proteases such as pep C may aid in bacterial survival during 
conditions of nutritiona l deficiency. 
 
Human BLMH is encoded by a twelve-exon single copy gene mapped to chromosome 17q11.1-
11.2 by linkage analysis and in situ hybridization (Montoya et al., 1997; Ferrando et al., 1997) 
(GDB accession ID: 3801467; GenBank accession: X92106).  The gene structure reflects the 
small introns and exons common in other papain superfamily members, but differs in intron-exon 
boundary locations consistent with evolutionary divergence from related thiol proteases 
1.4 Gene structure and characterization 
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(Montoya et al., 1997, Ferrando et al., 1997).  BLMH contains least two known polymorphic 
sites, a CCG-trinucleotide repeat 134 base pairs 5’to the ATG start site and a single base pair 
substitution A1450G that results in either a valine or isoleucine residue (I443V) (Bromme et al., 
1996; Ferrando et al., 1997).   
The human BLMH promoter has not been well characterized.  The cloned 1.2 kb of the 
5’untranslated region (GenBank accession: Y14426) is GC rich and lacks a consensus TATA 
box, but contains a putative AP-1 site (-224 bp) and several consensus Sp1 sites (Ferrando et al., 
1997).  Although initial surveys of tissue expression patterns found BLMH mRNA present in 
most samples (Bromme et al., 1996; Ferrando et al., 1997), available in situ hybridization and 
immunohistochemistry studies suggest that RNA and protein expression is not homogeneous 
(Namba et al., 1999; Takeda et al., 1999;  Malherbe et al., 2000).  Detailed, reliable expression 
pattern characterization is currently lacking.   
Murine Blmh, which lies on the systenic region of chromosome 11(GenBank accession 
NM178645; EMBL accession Q8BLZ4) (Okazaki et al., 2002), lacks the human –134 CCG 
trinucleotide repeat polymophism.  The putative proximal promoter does, however, display 
regions of remarkable conservation between mouse and human (69% identity between human –
171 to –862 and 97% identity between human –179 and –279) suggesting the presence of 
important regulatory elements in these regions (GenBank accession AL603842.9). 
 
BLMH is an aminopeptidase with a broad specificity for in vitro chromogenic substrates except 
those initiated by proline (Enenkel et al., 1993; Chapot-Chartier et al., 1994; Bromme et al., 
1.5 Protein activity, structure and regulation 
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1996).  No or minimal activity is observed with N-terminal protected peptide substrates 
(Bromme et al., 1996, Koldamova et al., 1998).  Unlike the lysosomal cathepsins that are most 
active at a slightly acidic pH (Turk et al., 1997), BLMH functions optimally at a pH of 7.2 
consistent with the lack of signal peptide and cytosolic localization (Bromme et al., 1996; 
Koldamova et al., 1999; O’Ferrell et al., 1999).   
Human BLMH is a 455 amino acid, 52 kD protein with an unusual multimeric structure.  
Although tetramers and other multimers have been noted (Enenkel et al., 1993; Koldamova et al., 
1998), most reports suggest the protease is a hexamer.  Crystalization of both the human and 
yeast protein reveal a ring barrel homohexamer containing a prominent central channel housing 
the active sites (Joshua-Tor et al., 1995; O’ Ferrell et al., 1999). Although the openings to the 
channel are relatively narrow (22Å), the central region is wider, approximately 45Å in diameter 
and 30Å in length.  Physical sequestration of active sites is seen in other self-compartmentalizing 
proteases such as the yeast 20S proteasome, the serine protease DegP from E. coli, and the 
tricorn protease from T. acidophilum (Vandeputte-Ruttene and Gros, 2002).   Sequestration of 
the catalytic activity prevents indiscriminate proteolysis and permits selective entry of potential 
protein substrates.  Entry to the BLMH central channel through the narrow axial opening would 
necessitate either peptide or partially unfolded protein substrates (Joshua-Tor et al., 1995).  
Alternatively, larger molecules could access the active site following structural rearrangement of 
the monomeric subunits potentially mediated by other macromolecules (Joshua-Tor et al., 1995).  
Protein partner screening in a yeast two-hybrid system has revealed interactions between BLMH 
and ubiquitin-conjugating enzyme 9 and the ribosomal proteins L11 and L29 (Koldamova et al., 
1998; Koldamova et al., 1999).  The physiological significance of these interactions is unknown, 
but may suggest a role in protein modification and degradation.       
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Three structural domains are defined in the BLMH monomer: a catalytic domain, a 
helical domain and a hook domain (Joshua-Tor et al., 1995; O’Ferrell et al., 1999).  The catalytic 
domain displays a typical papain like architecture despite lacking the multiple disulfide bonds 
common in related proteases.  The helical and hook domains mediate interactions between 
adjacent monomers.  These interactions result in tightly associated dimers and, in fact, the 
hexamer has been described as a trimer of dimers (Joshua-Tor et al., 1995).   
The C-terminus of BLMH is an important regulator of enzymatic activity.  The 
penultimate eight residues are absolutely conserved in all known forms of the enzyme (Mata et 
al., 1997; Koldomova et al., 1998).  In the crystal structure, the BLMH C-terminus projects into 
its active site cleft resembling the alignment of the reversible inhibitor leupeptin within the 
papain active site (Joshua-Tor et al, 1995). The terminal caboxylate appears to interact with the 
N-terminus of the peptide substrate positioning it within the active site (Zheng et al., 1998).  N-
terminally acetylated and nonacetylated peptide substrates bind with a similar Km, but the 
acetylated substrate displays a 50 fold decrease in Kcat indicating the need for an unprotected N-
terminus for proper substrate positioning (Zheng et al., 1998).  Surprisingly, C-terminal deletions 
result in loss of aminopeptidase activity, gain of endopeptidase function and, acquired sensitivity 
to leupeptin (Mata et al., 1997; Koldomova et al., 1998; Zheng et al., 1998).  Thus, the C-
terminus appears to function as a regulator of enzymatic activity by limiting access to the active 
site cleft and positioning of the substrate.  Regulation of enzymatic activity by structural features 
that limit substrate access is common among the cathepsins.  For example, cathepsin B possesses 
a 20 residue occluding loop that restricts the active site and provides, together with two 
histidines, an anchor for the C-terminal carboxylic group of the substrate making the enzyme a 
carboxypeptidase (Turk et al., 1997, Nagler et al., 1999).  Cathepsin H retains an eight  residue 
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long disulfide bonded section of the propeptide chain that blocks the active site making the 
enzyme an aminopeptidase (Turk et al., 1997; Vasiljeva et al., 2003).  
 In addition to lysosomal compartmentalization and physical restriction of substrate 
access, cathepsin activity is modulated by synthesis of inactive precursor and presence of native 
inhibitors, the cystatins.  BLMH lacks a propeptide, but does undergo cleavage of the terminal 
amino acid residue by autocatalysis (Joshua-Tor et al., 1995; Zheng et al., 1998).  The 
importance of this processing in the physiological regulation of protease is unknown and no 
native inhibitors have to date been identified (Takeda et al., 1996). 
 
Although papain superfamily members have been widely viewed as mediators of protein 
catabolism, recent discoveries reveal that these proteases have specific, non-redundant functions.  
For example, cathepsin K is crucial for normal bone remodeling (Chapman et al., 1997; Saftig et 
al., 1998), cathepsin L has a role in epidermal homeostasis and regulation of hair follicle 
morphogenesis and cycling (Roth et al., 2000), and cathepsin S and L are essential for the normal 
functioning of the immune system (Nakawaga et al., 1998; Nakagawa et al., 1999; Shi et al., 
1999).  The physiological functions of BLMH remain unknown although recent studies suggest 
the protease may play a role in dermal integrity and Alzheimer’s disease (Montoya et al., 1998; 
Schwartz et al., 1999; Lefterov et al., 2000). 
 
1.6 Physiological functions 
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In yeast, the BLMH ortholog Blh1/Gal6 is biochemically and genetically identical to lap 3, one 
of four characterized aminopeptidase activities against leucine beta-naphthylamide (Trumbly and 
Bradley, 1983, Enenkel et al., 1993).  Although Blh1/Gal6 is non-essential for normal growth 
(Kambouris et al., 1992; Enenkel et al., 1993), deletion of the protease ablates hydrolyzing 
activity against acidic chromogenic peptide substrates (Enenkel et al., 1993).  Blh1/Gal6 is a 
single copy gene mapped to yeast chromosome XIV about 500 bp upstream of the calcium 
dependent serine protease KEX 2 (Kambouris et al., 1992).  The Blh1/Gal6 gene is induced by 
the positive galactose regulon transcriptional activator Gal 4 through an upstream activating 
sequence (UAS) located –150 bp from the ATG start site (Zheng et al., 1997).  The 
transcriptional activator IMP 2, which is involved in glucose derepression of the maltose, 
galactose, and raffinose utilization pathways, also influences both constitutive and inducible 
Blh1/Gal6 expression (Alberti et al., 2003).  Surprisingly, Blh1/Gal6 appears to be a negative 
regulator of galactose regulon at the RNA level (Zheng et al., 1997; Ostergaard et al., 2001).  
Deletion of Blh1/Gal6 results in a 2-5 fold higher expression of the GAL1, GAL2, GAL7 and 
MEL1 genes, but not other inducible genes unrelated to the galactose regulon (Zheng et al., 
1997).  Blh1/Gal6 binds to single stranded DNA and RNA in a sequence independent fashion 
due to a strong positive electrostatic potential in the central channel (Xu et al., 1994; Zheng et 
al., 1997), a feature that is not conserved in the human protease (O’Farrell et al., 1999).  The 
physiological significance of this observation is unclear and the mechanism for the action of 
Blh1/Gal6 on the galactose regulon is unknown.  
 
1.6.1 Yeast  
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Deletion of murine Blmh by homologous recombination results in neonatal lethality, reduced 
body weight and epidermal abnormalities (Schwartz et al., 1999).  Although Blmh null mice are 
viable and fertile, only 65% of the expected number based on a Mendelian distribution survives 
to weaning.  Surviving animals are smaller than littermate controls and often present with 
generalized scaling and sloughing of the skin over the entire body.  In adult null animals, 
variably penetrant dermatopathology is confined to the tail and characterized by swelling, 
erythmatosis, necrosis and autoamputation.  The tail pathology is inducible by low humidity 
conditions in a manner similar to rodent ringtail. The pathophysiology of both Blmh tail 
dermatitis and rodent ringtail are unknown.  Gross evaluation of other tissues from null mice 
revealed no further abnormalities.  These findings indicate that in mice, BLMH has non-
redundant and physiological important functions. 
 
BLMH has been genetically associated with increased risk for Alzheimer’s disease (AD) 
(Montoya et al., 1998; Papassotiropoulos et al., 2000).  Genotyping of AD cases and controls in 
two independent populations for the twelfth exon A/G polymorphism (I443V) revealed that the 
G/G frequency was overrepresented in AD cases (12.7% vs. 6.6%; odds ratio 2.05, P=0.009) 
(Montoya et al., 1998).  When the data were stratified by apolipoprotein (APOE) genotype, the 
increased risk was found to segregate in the non APOEe4 population.  Other genetic studies have 
failed to discern this association (Farrer et al., 1998; Namba et al., 1999; Prince et al., 2001; 
1.6.2 Mice 
1.6.3 Humans 
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Emahazion et al., 2001).  Epidemiological and genetic studies suggest a significant portion of 
late onset AD is attributable to genetic factors; however, these proposed susceptibility genes 
probably exert only small to modest effects (Risch et al., 2000).  Although over 100 genes have 
been reported associated with AD, only one, APOE has been consistently confirmed as a 
susceptibility risk factor.  The most likely reasons for inconsistencies between studies are 
population stratification and heterogeneity (Bertram and Tanzi et al., 2001; Emahazion et al., 
2001; Finckh, 2003).   
Surprisingly, in a family based association study, the BLMH twelfth exon polymorphism, 
but not the trinucleotide repeat, was found to exhibit modest transmission disequilibrium with 
autistic disorder (TDT c2 5.24, P=0.02) (Kim et al., 2002).  Significant transmission 
disequilibrium was also found with the serotonin transporter gene (SLC6A4) located 
approximately 15 kb downstream from BLMH (Kim et al., 2002).  The role of BLMH in the 
pathogenesis of AD and other psychiatric disorders remains unclear based on current genetic 
studies. 
BLMH is expressed in the human brain from which it was cloned and also purified to 
homogeneity (Chang and Abraham, 1996; Ferrando et al., 1996).  However, the regional and 
cellular distribution of BLMH in the central nervous system (CNS) remains to be characterized.  
Published immunohistochemisty suggest protein expression is primarily neuronal, although in 
situ hybridization shows the strongest signals originating from clusters of cells within the white 
matter (Namba et al., 1999; Raina et al., 1999; Malherbe et al., 2000).  Currently, 
immunohistochemistry studies are limited by a lack of reliable antibodies. 
Overexpression of BLMH in cell culture appears to influence the processing of the 
amyloid precursor protein (APP).  The amyloid beta (Ab) peptide is proteolytically derived from 
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APP and a hallmark for AD pathology.  Ab  is also believed to have a causative role in the 
pathogenesis of the disease (Selkoe, 2000; Hardy and Selkoe, 2002).  In CHO and 293 cells, 
ectopic overexpression of proteolytically active BLMH results in an approximately fifty percent 
increase in the secretion of Ab  (Lefterov et al., 2000; Lefterov et al., 2001). BLMH is not 
thought to directly cleave APP to generate Ab , and the mechanism for the effect is unknown.  
Ab  secretion is known to be modulated by several proteins such X11 and Fe65, which alter APP 
stability and subcellular localization (Sastre et al., 1998; Sabo et al., 1999; Kimberly et al., 
2001).  Consistent with the BLMH overexpression data, treatment of CHO cells with the 
protease inhibitor E64d results in a significant reduction in Ab  secretion indicating a papain like 
cysteine protease may modulate APP processing (Figueiredo-Pereira et al., 1999).  These results 
suggest that BLMH or another papain superfamily cysteine protease may affect APP processing 
through a physiologically relevant process. 
BLMH is also a candidate aminopeptidase for the processing of major histocompatability 
complex class I (MHC I) epitopes (Stolze et al., 2000).  MHC I molecules are cell surface 
peptide receptors and components of an intracellular immune surveillance system (York et al., 
1999; Saveanu et al., 2002).  Eight to nine residue long peptide epitopes are primarily generated 
by the ubiquitin-proteasome system in the cytoplasm.  These are then transported into the 
endoplasmic reticulum (ER) by the transporter associated with antigen presentation (TAP) and 
transferred to MHC I molecules by a multiprotein loading complex (Lankat-Buttgereit et al., 
1999; York et al., 1999; Paulsson et al., 2004).  Proteolytic regulation of epitope generation can 
be modulated by treatment of cells with interferon gamma (INFg) (Fruh and Yang, 1999).   
Emerging evidence suggests that other proteases in addition to the proteasome are 
involved in production of peptide epitopes (Goldberg et al., 2002; Kessler et al., 2002; Saveanu 
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et al., 2002).  Studies with proteasome inhibitors and N-terminally extended antigenic peptides 
demonstrate the presence of putative cytosolic aminopeptidases involved in epitope processing 
(Goldberg et al., 2002; Kessler et al., 2002).  Fractionation of cellular extracts capable of 
trimming N-extended precursors of vesicular stomatitis virus protein has revealed that BLMH is 
a candidate protease for MHC I epitope generation (Stolze et al., 2000).  BLMH has been 
hypothesized to function downstream of the proteasome in degradation of peptide substrates 
based on its subcellular localization and activity profile (Zheng et al., 1998).  Other 
aminopeptidases that are postulated to function in MHC I epitope processing include the 
cytosolic leucine aminopeptidase (Beninga et al., 1998) and puromycin sensitive aminopeptidase 
(Stolze et al., 2000), and the endoplasmic reticular aminopeptidase associated with antigen 
presentation (ERAAP) (Serwold et al., 2002).  Both leucine aminopeptidase and ERAAP are 
inducible by INFg (Beninga et al., 1998; Serwold et al., 2002). It is unknown if BLMH 
expression is modulated by INFg. 
In the CNS, MHC I molecules may also play a role in normal neuronal development and 
synaptic plasticity.  Although the expression of MHC I in neurons was initially believed to be a 
mechanism for flagging of electrically silent neurons for culling during infection (Neumann et 
al., 1995), more recent studies have shown that MHC I molecules are also expressed in neurons 
that undergo activity dependent changes (Corrveau et al., 1998).  During development, 
spontaneously generated activity coupled with MHC I surface expression is required in the 
remodeling of retinal axons from each eye into the layers within the lateral geniculate nucleus 
(Huh et al., 2000).  This requirement is evidenced by the significant alteration of this projection 
in mice lacking b2-microglobulin (Zijlstra et al., 1990) and/or TAP 1 (Dorfman et al., 1997) and 
also in mice lacking CD3z (Love et al., 1993), a MHC I receptor subunit.  b2-microglobulin and 
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the TAP 1 transporter are molecules required for the assembly of nearly all cell surface class I 
MHC molecules (Dorfman et al., 1997).  Synaptic plasticity is also altered in the MHC I 
deficient genetically modified mice. N-methyl-D-aspartate receptor-dependent long-term 
potentiation is enhanced and long-term depression is absent in the Schaffer collateral CA1 
synapse of the hippocampus of the genetically modified adult mice with MHC I expression 
deficits (Huh et al., 2000).  MHC I dependent neuronal development and plasticity could require 
peptide signals (Rall et al., 1995; Corriveau et al., 1998) and consequently pose an important role 
for proteases involved in generating antigenic peptides. 
BLMH and its orthologs have evolved multiple unique and specific functions from a role 
in the galactose regulon in yeast to possibly processing of MHC I epitopes in mammals.  Further 
characterization and elucidation of the physiological roles of this protease is not only of 
academic interest, but also of potential importance to understanding the possible functions 
BLMH may have in human disease. 
 
BLMH is a multifaceted cysteine protease with putative specific biological functions in immune 
surveillance and possibly neurodegeneration.  This thesis project has focused on the potential 
unique physiological functions that BLMH may have in the CNS and has utilized the Blmh null 
mouse as a valuable tool for evaluation of these functions.  The hypotheses are that (1) deletion 
of murine Blmh results in alterations in CNS function, (2) genetic polymorphism in the BLMH 
promoter results in differential expression potentially accounting for increased AD risk with 
1.7 Hypothesis and specific aims 
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certain genotypes, and (3) BLMH expression is modulated by factors that alter MHC I epitope 
processing. 
The Specific Aims are:  (1) to determine if deletion of the murine Blmh affects behavioral 
phenotype;  (2) to evaluate the trinucleotide repeat polymorphisms of the BLMH promoter for 
differential expression among the polymorphic variants; (3) to determine if Blmh expression is 
altered by induction of the cell stress response or by cytokines known to upregulate MHC I 
epitope processing. 
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All mice were housed four or five to a cage and maintained under controlled conditions with a 
twelve hour light cycle (lights on at 7 am) and free access to food and water.  Hybrid [129S6-
Blmhtm1Geh/J X B6.129 Blmhtm1Geh/J]F1 Blmh null animals and littermate controls were bred from 
female 129S6-Blmhtm1Geh/J  backcrossed 7-9 generations to 129S6/SvEv (Taconic, Germantown, 
NY) and male B6.129Blmhtm1Geh/J backcrossed 9-11 generations to C57BL/6J (Jackson Labs, 
Bar Harbor, Maine).  B6.129 Blmhtm1Geh/J null and wild type animals used for CNS 
immunohistochemistry were bred from male and female heterozygote B6.129 Blmhtm1Geh/J. All 
experimental procedures were approved by the Animal Care and Use Committee of the 
University of Pittsburgh.  
Genomic DNA for genotyping was isolated from tail clippings taken at weaning (Laird et 
al., 1991) and further purified with InstaGene Matrix (BioRad, Hercules, CA) per manufacturers 
instructions.  Animals were genotyped by three primer PCR (Schwartz et al., 1999).  The 
forward primer p1 (CACTGTAGCTGTACTCACAC) recognized both the null and wild type 
alleles.  Reverse primer p2 (GCGACAGAGTACCATGTAGG) annealed within exon 3 giving 
rise to a 0.6 kb amplicon, whereas reverse primer p3 (ATTTGTCACGTCCTGCACGACG) 
annealed within the targeted deletion neomycin cassette producing a 0.95 kb amplicon.  The PCR 
mixture (25 ml) contained 6 ml InstaGene purified DNA, 2 mM Mg2+, 0.2 mM dNTP, 2 mM p1, 
0.8 mM p2, 6.4 mM p3 and 0.5 units of Taq polymerase (Invitrogen, Carlsbad, CA).  The thermal 
cycling reaction was run on a PTC-100TM (MJ Research Inc., Watertown, MA) with 34 cycles 
2 MATERIALS AND METHODS 
2.1 Blmh null mice:  maintenance and genotype determination 
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of 92°C for 30s, 65°C for 40s and 72°C for 90s.  Amplicons were resolved on a 1% agarose gel 
and stained with ethidium bromide.   
 
Young (less than 8 months) or aged (greater than 14 months) groups of male and female Blmh 
null and wild type littermate controls were tested in a variety of established behavioral paradigms 
to evaluate locomotion and learning and memory.  Most animals were tested in multiple 
paradigms beginning with rotarod testing and contextual fear conditioning followed by open 
field testing and evaluation in the water maze. 
 
Mice were tested for seven consecutive days on a 3 to 19 rpm accelerating Ugo Basile Model 
7650 rotarod apparatus (Ugo Basile, Camerio, Italy).  Each animal was scored for time on 
rotarod defined as latency to fall from the apparatus during the180 s trial. 
 
Locomotion and exploratory behavior were evaluated for each mouse.  Each animal was 
placed into an open field chamber (28 x 28 x 40 cm) (MED Associates, St. Albans, VT) for 10 
minutes and the velocity, distance, location and duration of travel bouts, rearing and occurrence 
2.2 Animal behavioral studies 
2.2.1 Rotarod testing 
2.2.2 Open field testing 
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of stereotypical behaviors were recorded.  Center was considered the inner 50% of the testing 
surface. Open field testing was performed in collaboration with Dr. Edda Thiels, of the 
Department of Neuroscience, University of Pittsburgh. 
 
Learning to fear both a tone that was paired with a foot shock and the context in which the tone-
shock pairing was presented was evaluated using contextual fear conditioning (Paylor et al., 
1994).  Mice were transferred to the conditioning chamber and after an initial acclimatization 
period of 2 min, animals were presented with two pairings of a 30 s tone (80dB, 2000 Hz) with a 
2 s foot shock (0.75 mA) administered during the last 2s of the tone.  Pairings were separated by 
2 min and mice were returned to their home cages 30 s after the last shock presentation.  The 
conditioning chamber was custom built at the University of Pittsburgh.   
 Approximately 24 h later, mice were tested for contextual conditioning.  Mice were 
placed into the conditioning chamber for 5 min and freezing behavior was scored.  Freezing was 
scored manually and defined as absence of movement except respirations.  For the cued test, 
mice were placed into a novel context and scored for freezing for 3 min before and 3 min during 
presentation of the tone.  Contextual fear conditioning testing was performed in collaboration 
with Dr. Edda Thiels. 
Light-dark testing was used to evaluate anxiety, which was reflected by time spent in the 
darkened chamber.  Each animal was placed into a 50 % darkened chamber (28 x 28 x 40 cm) 
(MED Associates) for 10 minutes and the velocity, distance, location and duration of travel 
bouts, rearing, occurrence of stereotypical behaviors, and time spent in light and dark were 
2.2.3 Contextual fear conditioning and light-dark box testing 
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recorded.  Light-dark testing was performed in collaboration with Dr. Edda Thiels, of the 
Department of Neuroscience, University of Pittsburgh. 
 
 Pain sensitivity was determined by the hot plate test.  The animals were placed on a 25.5 
x 25.5 cm surface (Columbus Instruments, Columbus, OH) heated to 52° C for a maximum of 5 
min.  Pain threshold was accessed by latency to paw licking, shaking and/or jumping.  Animals 
exhibiting significant distress were immediately removed from the heated surface.  Hot plate 
testing was performed in collaboration with Dr. Edda Thiels. 
 
Spatial learning and memory were evaluated in the Morris water maze (Morris, 1984).  The 
water maze consisted of an 83 cm diameter tank filled with water to a depth of 29 cm obscuring 
a translucent platform submerged 1 cm below the surface of the water.  Visual cues in the testing 
room and platform location remained fixed for all trials.  On five consecutive training days, each 
animal received four 120 s training trials.  Animals that failed to find the submerged platform 
during the trial were manually placed on the platform for 30 s.  Performance during training was 
evaluated as average latency to find the platform for each of the training days. Probe trials were 
conducted following completion of training.  The platform was removed from the tank and swim 
pattern was recorded for 60 s using a video tracking system (Chromotrack 3.0, San Diego 
Instruments, San Diego, CA).  Probe trials were scored by time spent in each of the four pool 
2.2.4 Hot plate testing   
2.2.5 Water maze testing 
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quadrants during the test.  Following the probe trials, visual acuity of each mouse was 
determined using a visible platform that was exposed 1.5 cm above the level of the water and 
marked with colored tape.  For data analysis, only the results from probe trial 1 were evaluated.  
Overall, probe trials 1 and 2 yielded similar results. Water maze testing was conducted in 
collaboration with Dr. Edda Thiels and Dr. Edward Dixon of the Department of Neurological 
Surgery, University of Pittsburgh. 
Animal behavioral data were analyzed with Stat View (SAS Institute, Cary, NC).  Each group of 
animals was individually evaluated for trial and genotype effects.  If a replicate group of the 
same sex and age mice was tested on separate dates, then the groups were compared for 
differences and pooled if no significant differences were found.  Male and female groups in the 
same age category were then compared for gender effects and pooled if no differences were 
observed. Pooled groups were re-evaluated for trial and genotype effects.  Finally, young and 
aged pooled groups were compared to each other.  Three values for velocity (cm/s) from the 
open field test were discarded as outliers based on Grubb’s test (Iglewicz and Hoaglin, 1993); no 
other values were omitted from any other of the datasets. Data were evaluated by c2, two-tailed t-
test or two-way repeat measures ANOVA followed by Bonferroni posthoc tests and individual 
contrasts when appropriate.  The differences between means were accepted as significant at the P 
< 0.05 level.  
 
 
2.2.6 Statistical analysis of behavioral data 
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Each animal was deeply anesthetized by intraperitoneal injection of 125 mg/kg sodium 
pentobarbitol prior to sequential transcardial perfusion of physiological saline and 4% 
paraformaldehyde fixative infused at controlled pressure using a peristaltic pump (Cole-Palmer, 
Vernon Hills, IL).  The isolated brain was postfixed for 2 h and placed in phosphate buffered 
sucrose solution at 4° C overnight.  
 
For preparation of free floating sections, the brain tissues were serially sectioned in the coronal 
plane at 35 mm /section using a sliding microtome equipped with a freezing stage (Leitz 
Physitemp).  Sections were sequentially collected in six bins of cryoprotectant and stored at          
-20° C until processed for immunohistochemistry.  Paired null and wild type tissue sections were 
stained with Nissl or processed for immunohistochemistry using the avidin-biotin modification 
of the immunoperoxidase procedure.  Briefly, tissues were washed four times with 0.1M sodium 
phosphate buffer to remove cryoprotectant solution.  Sections were then transferred to diluted 
primary antibody (Appendix A) in 10mM sodium phosphate buffer containing 0.3% Triton X-
100 and 1% normal donkey serum.  Following overnight incubation at 4° C, the tissues were 
washed three times in 10 mM sodium phosphate buffer followed by 1 h incubation in affinity 
2.3 Immunohistochemistry 
2.3.1 Animal perfusions 
2.3.2 Immunohistochemistry of free floating sections 
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purified biotinylated donkey secondary (Jackson ImmunoResearch Laboratories, West Grove, 
PA).  The sections were incubated in ABC complex for 90 min using reagents from the Vector 
Elite Kit (Vector Laboratories, Burlingame, CA), washed in 10 mM phosphate buffer, and then 
incubated in a 0.1 M Tris-saline buffer containing diaminobenzidine (DAB) for 10 min.  The 
immunoperoxidase reaction product was visualized by adding H202.  Sections were mounted on 
gelatin coated slides, dried at room temperature, dehydrated in a graded ethanol series, cleared in 
xylene and coverslipped with Cytoseal60 (Richard Allan Scientific, Kalamazoo, MI). 
 
Brain tissues were placed in phosphate-buffered saline (PBS) overnight and then paraffin 
embedded.  For immunohistochemistry, paraffin embedded tissue sections were deparaffinized 
with Histoclear (National Diagnostics, Atlanta, GA), rehydrated, and treated with 3% hydrogen 
peroxide (Sigma Chemical Co., St. Louis, MO) for 30 min to quench endogenous peroxidases.  
Sections were rinsed with PBS and incubated in TNG blocking buffer (DuPot NEN, Boston, 
MA) for 30 min.  After overnight incubation at 4° C with rabbit anti-GFAP antibody (1:500) 
(Daco, Winnipeg, CA), the sections were rinsed in PBS and then incubated at room temperature 
for 1 h with biotynilated goat anti- rabbit IgG (1:200, Biogenex, San Ramon, CA).  Chromagen 
reactions were developed with 3-amino-9-ethylcarbazole (AEC, Biogenex) and counterstained 
with Mayer’s hematoxylin. 
All sections were visualized and recorded with a Leica DMR microscope equipped with a 
DC100 digital camera (Leica Microsystems, Wetzlar, Germany).  Immunohistochemistry studies 
2.3.3 Immunohistochemistry of paraffin embedded sections 
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were conducted with the assistance of Dr. Patrick Card of the Department of Neuroscience, 
Univeristy of Pittsburgh, and the Neuropathology Laboratory at the University of Pittsburgh. 
 
All exons of the BLMH gene with their flanking intronic boundary sequences as well as 1.2 kB 
of the 5’upstream region (Ferrando et al., 1998) were PCR amplified and screened for 
polymorphisms by direct cycle sequencing and single strand conformational polymorphism 
analysis (SSCP). Each exon and overlapping regions of the 5’ upstream sequences were 
amplified from human genomic DNA from 10 Pittsburgh Alzheimer’s Disease Research Center 
(ADRC) autopsy confirmed cases and 10 ADRC controls (Table 1). Amplicons were sized on 
ethidium bromide stained 1% agarose gel with a 1 kb ladder molecular size marker (Invitrogen). 
Confirmation of the identity of the PCR products and screening for polymorphisms were 
performed by dye labeled terminator direct cycle sequencing using the DNA Sequencing Kit 
(Applied Biosystems Inc., Foster, CA).  Sequencing products were analyzed on an ABI Prism 
377 automatic DNA sequencer (Applied Biosystems Inc.).  DNA sequences were assembled 
using Sequencher v. 3.0 (Gene Codes Corp., Ann Arbor, MI).   
For SSCP analysis, PCR amplicons were separated on 4-20% TBE polyacrylamide precast 
gels (NOVEX, San Diego, CA) run on Mighty Small II Vertical Electrophoresis Unit (Hoefer, 
San Francisco, CA) for 2.5 h at 20 mA with a temperature gradient of  -7° to 20°C 
(Programmable Temperature Controller, Polyscience, Niles, IL).  Gels were visualized by 
staining with SYBR Green II (Molecular Probes, Eugene, OR) for 20 min followed by inspection 
using the Still Video Imaging System (Eagle Eye II, Stratagene, La Jolla, CA). 
2.4 BLMH Polymorphism screen   
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Table 1 BLMH polymorphism screen primers  
 
5’  
PRIMER 
 
SEQUENCE 
 
Annealing 
(°C) 
 
Amplicon 
(kb) 
-1210 FORWARD GTTCCTTAGAACTGCGATG 58 1178 
-33 REVERSE TTCCAGGGT CCTTGGGC   
-747 FORWARD GAAGAGCTTGGTTCCCATTCC 58 219 
-529 REVERSE GCCAAAAGGGAGCTCGAG   
-534 FORWARD TTTGGCTTCTCACAAGGCTTCCTGG 60 201 
-334 REVERSE CGCGCAGGACCGCACAGATGG   
-360 FORWARD CGGCAGACCATCTGTGCGGTCC 60 197 
-164 REVERSE GGGAGGCTGAGGCTGGAGAAACG   
EXON     
1 FORWARD CGCCGAGCCGGTTTCCTT (-140) 60 162 
 REVERSE TTGAGTCCCGAGCTGC (+20)   
2 FORWARD CCAACAGGACTGAATTCG 58 209 
 REVERSE CCACACCTGAGCTCTTCTG   
3 FORWARD CAGTGCAGTCTATGTGAACC 56 216 
 REVERSE GGCAGGCTATAACTGGAA   
4 FORWARD CTCTTTAGGTTGAACGCTG 56 189 
 REVERSE CATGCTGAGTTTCAGTTCC   
5 FORWARD AGAAAAATATGGTGTTATCCCTAAGAAATGC 55 110 
 REVERSE CCTGCTTCATATATTGTACC   
6 FORWARD GGTAACTGTTGGAGAGTGCT 56 136 
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 REVERSE TACCTCCTCCATCATGACG   
7 FORWARD GATATTCCGAGTGGTGTG 56 184 
 REVERSE CAGTGACTACCAGTGCCA   
8 FORWARD GTTGCTTGACATTCCTGG 56 177 
 REVERSE AGGAAGTCAATGGGCTG   
9 FORWARD CAACAACCAGCCCATTGACTTCC 58 257 
 REVERSE GAGATTCATGTCACTGAGGCCCAGC   
10 FORWARD CAGCTATGACCATGAGTTAG 58 126 
 REVERSE CATACCTTCTCTGAGACAGC   
11 FORWARD CAGGATGATCAGGATGG 56 82 
 REVERSE TGAGGCTCACCTTTGTGG   
12 FORWARD TCTCCAGGTTACCTGTGC 56 77 
 REVERSE CTCTTCAGGGACATGCTTC   
 FORWARD GGAAGCATGTCCCTGAAGAGGTGC 58 160 
 REVERSE CCTGGATCTGTCCTTTGCAGCTACG   
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1.2 kB of the 5’ upstream region of the putative BLMH promoter was amplified with Pfu 
polymerase (Stratagene, La Jolla, CA) from genomic DNA from ADRC cases and controls who 
differed in genotype at the –134 bp trinucleotide repeat polymorphism.  The primers used were: 
5’-GCCTGGTACCGTTCCTTAGAACTGCGATG-3’ (-1210 5’BLMH) and 5’-
GCTAAGCTTTCCA GGGTCCTTGGGC-3’ (-33 5’ BLMH).  Amplified fragments were 
incubated with excess dATP and Taq polymerase (Invitrogen) at 72°C for 10 min to add 3’ 
overhangs and were then ligated into the TA cloning vector pCR 2.1 (Invitrogen) with T4 ligase 
(Invitrogen).  Clones were screened by restriction enzyme digestion with Kpn I and Hind III 
(New England Biolabs, Beverly, MA) and direct cycle sequencing.  Positive clones were 
subcloned into the pGL3 basic vector (Promega, Madison, WI).  The pGL3-5’BLMH  plasmids 
were amplified in DH5a E. coli (Invitrogen) and grown on ampicillin-containing LB agar plates.  
The plasmids were then purified by Wizard miniprep (Promega) and the constructs were verified 
by double digestion with Kpn I and Hind III (New England Biolabs) as well as by direct cycle 
sequencing using an ABI 377 (Applied Biosystems Inc.). 
 
 
Human BLHM cDNA was amplified by long distance PCR with Elongase (Invitrogen) using 
cDNA kindly provided by Dr. D. Bromme (Mt. Sinai School of Medicine) and the following 
2.5  Cloning and vectors 
2.5.1 Construction of pGL3-BLMH vectors 
2.5.2 Construction of EGFP-BLMH vector 
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primers: 5’-CGAAGCTTGCAGATGAGCAGCTCG-3’ (BLMH exon 1) and 5’-
CCGGTACCGTATCACTCACTCAGCCAA-3’ (BLMH exon 12).  The PCR amplicon was 
cloned into the enhanced green fluorescent protein (EGFP-C2) vector (Clonetech, Palo Alto, CA) 
using the Hind III and BamHI restriction endonuclease cleavage sites.  The EGFP-BLMH 
plasmid was amplified in DH5a E. coli (Invitrogen) and grown on kanamycin containing LB 
agar plates.  The plasmid was then purified by Wizard miniprep (Promega) and the construct was 
verified by double digestion and direct cycle sequencing using an ABI 377 (Applied Biosystems 
Inc.). 
 
pGL3 basic vector, containing firefly luciferase lacking any defined promoter elements, pGL3 
control vector, with the luciferase construct driven by the SV40 promoter, and the pRL TK 
vector which expresses renilla luciferase under the control of the thymidine kinase promoter 
were purchased from Promega.   EGFP-C2 was obtained from Clonetech.   
 
Luciferase assays were run using the Dual-Luciferase Reporter Assay System (Promega) per 
manufacturers directions.  Briefly, pGL3 and pRL TK vector concentrations were measured with 
a DU640 spectrophotometer (Beckman Instruments, Fullerton,  CA) and verified by digestion 
with Hind III (New England Biolabs) and electrophoresis on 1% agarose gel stained with 
2.5.3 Vectors 
2.6 Luciferase assays 
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ethidium bromide.  Dilutions of digested pGL3 basic vector of known concentrations were used 
as standards.  DNA concentrations were determined using the Still Video Imaging System (Eagle 
Eye II, Stratagene).  Cells were co-transfected with pGL3 and pRL TK vectors 24 h prior to 
assaying and were harvested by incubation with passive lysis buffer (Promega).  Cell lysate was 
then mixed with Luciferase Assay Reagent II (Promega) and after a 2 s delay, firefly luciferase 
luminescence was measured.  Stop and Glo (Promega) was then added to quench the firefly 
luciferase and concomitantly activate the renilla luciferase and renilla luminescence was 
measured.  All luciferase measurements were performed on a Victor 2 multilabel, multiplate 
reader (Perkin Elmer, Boston, MA) with a dual auto injector system.   Luminescence from the 
pGL3 vectors was normalized to renilla luminescence. 
 
Total RNA was purified from murine cerebral cortex with Trizol reagent (Invitrogen) per 
manufacturers instructions.  The primer 5’-ACCATCATTTGCAGGGTTCATAAG-3’ was used 
to prime cDNA synthesis from 500 ng of total RNA using reverse transcriptase (Invitrogen).   
The RNA:DNA hybrids were purified with GLASS MAX spin cartridge (Invitrogen) and dA-
tailed with terminal deoxynucleotidyl transferase.  Tailed cDNA was amplified by two rounds of 
PCR.  In the first round, the primers were 5’-CAGGTAAGATTGGCTAAACTC-3’ (BLMH 
exon 3) and anchor-primer 5’-GGCCACGCGTCGAC TAGTACGGGIIGGGIIGGGIIG-3’.  
Amplification was performed using the following cycling conditions:  94 °C 1 min, 55 °C 30s 
and 72 °C 1 min.  In the second round of PCR, the primers were 5’-
2.7 5’RACE 
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GTGATTGGCTTGCCCTCCTGG-3’ (BLMH exon 2) and 5’-GGCCACGCGTCGACTAGTAC-
3’.  Amplicons from nested PCR were sequenced to identify the transcriptional start sites. 
 
Total RNA was isolated from EOC20 cells using an RNeasy Kit (Qiagen, Valencia, CA). RNA 
concentrations were measured using a DU640 spectrophotometer (Beckman Instruments). 
Northern blotting was performed using NorthernMaxTM system (Ambion, Austin, TX) according 
to the manufacturer's instructions. Briefly, 5 µg of total RNA and Digoxigenin (DIG)- labeled 
RNA Molecular Weight Marker I (Roche Applied Science, Indianapolis, IN) were 
electrophoresed on 1% denaturing agarose gel containing 2.2 M formaldehyde, transferred to 
Nytran® SuPerCharge membrane (Schleicher & Schuell, Keene, NH) and UV cross- linked.  A 
1365-base pair DIG-labeled double-stranded DNA probe was generated by PCR amplification of 
the cloned BLMH cDNA with primers 5’-CGAAGCTTGCAGATGAGCAGCTCG-3’ (BLMH 
exon 1) and 5’-CCGGTACCGTATCACTCACTCAGCCAA-3’ (BLMH exon 12) using a PCR 
DIG Probe Synthesis Kit (Roche Applied Science). The probe was hybridized to the membrane 
overnight in ULTRAhybTM Ultrasensitive Hybridization Buffer (Ambion), and the membrane was 
processed using DIG Wash and Block Buffer Set (Roche Applied Bioscience). The hybridized 
probe and anti-DIG-alkaline phosphatase (AP) Fab fragments (Roche Applied Sciences) 
complex was visualized on x-ray film (Eastman Kodak Co., Rochester, NY) after incubation of 
the membrane with CDP-Star ultrasensitive chemiluminescent substrate for AP (Roche Applied 
Sciences). Membranes were reprobed with DIG-labeled actin RNA probe (Roche Applied 
Sciences) as a loading control.   For quantitation of RNA expression levels x-ray films were 
2.8 RNA isolation and Northern blotting 
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scanned by densitometry (SI, Amersham Biosciences, Piscataway, NJ) and analyzed using the 
ImageQuant software package (version 4.1, Amersham Biosciences). 
 
 
Recombinant rat g interferon and mouse recombinant tumor necrosis factor a were purchased 
from Calbiochem (La Jolla, CA).  Recombinant human g interferon was purchased from 
Biosource International (Camarillo, CA). 10 mM MG132, a proteasome inhibitor, in anhydrous 
DMSO was purchased from Calbiochem.  
 
All antibodies are listed in Appendix A.  Rabbit anti rat Blmh was a kind gift of Dr. Atsushi 
Takeda (Sagami Women’s University, Kanagawa, Japan).   Chicken anti-human BLMH was 
produced through Aves Labs (Tigard, Oregon) and the IgY fraction was affinity purified.  
Briefly, 5 ml IgY fractions were run over recombinant purified His-BLMH crosslinked to an 
Affi-15 affinity support (BioRad).  The column was washed with 100 mM sodium phosphate 
buffer at pH = 7.2 with increasing concentrations of sodium chloride and then eluted with pH = 
2.0 elusion buffer (100 mM glycine buffer with 10% 1,4-dioxane).  The affinity purified chicken 
2.9 Cytokines, protease inhibitors and antibodies 
2.9.1 Cytokines and protease inhibitors 
2.9.2 Antibodies 
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anti-BLMH was precipitated with 100% saturated ammonium sulfate, resuspended in PBS and 
dialyzed against PBS.  Rabbit polyclonal anti-heat shock protein 70 (SPA-812) was purchased 
from Stressgen (Victoria, BC, Canada); rabbit anti-proteasome 20S LMP 7 (PA1-972) was 
purchased from Affinity BioReagents (Golden, CO); rabbit anti-vinculin (H-300) was purchased 
from Santa Cruz.   
 
Blmh wild type and null murine embryonic fibroblasts (MEF) were established in culture from 
embryonic day (ED) 16-18 embryos and immortalized with Simian virus 40 large tumor antigen 
by Dr. D. Schwartz, Department of Pharmacology, University of Pittsburgh (Lefterov et al., 
2001).  MEF as well as HeLa human cervical carcinoma cells (HPV-positive) [American Tissue 
Culture Collection (ATCC), Manassas, VA] were maintained in Dulbecco's minimal essential 
medium containing 10% fetal bovine serum (HyClone, Logan, UT) and 1% penicillin-
streptomycin (Invitrogen).  Human embryonic kidney (HEK) 293 (ATCC) cells were maintained 
in minimal essential media containing 1.5 g/L sodium bicarbonate and 10% fetal bovine serum 
(HyClone).  Human neuroblastoma SHSY-5Y (ATCC) was maintained in 1:1 Eagle’s minimum 
essential media: Ham’s F-12 with 10% fetal bovine serum (HyClone). LADMAC cells (ATCC), 
which secrete colony stimulating factor 1, are derived from c-myc transfected murine bone 
marrow and were maintained in minimal essential media and 10% fetal growth serum.  Murine 
microglial cell line EOC20 (ATCC) was maintained in Dulbecco's minimum essential medium 
containing 10% fetal bovine serum and 20% LADMAC conditioned media.  Primary astrocyte 
and microglial cultures were isolated from the cerebral cortices of ED21 Sprague-Dawley rats by 
2.10 Cell culture 
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Dr. I. Lefterov, Department of Pharmacology, University of Pittsburgh, as previously described 
(Koldamova et al., 2003) and were maintained in Dulbecco's minimum essential medium 
containing 10% fetal bovine serum (HyClone).  All cultures were grown in a humidified 
atmosphere of 5% CO2 at 37 °C.   
 
Cells were transiently transfected using LipofectAMINE PLUSTM (Invitrogen) in serum-
containing medium according to the manufacturer's instructions. Briefly, DNA and lipid 
complexes were incubated for 20 min in OPTIMEM (Invitrogen) and then added to cell cultures.  
Media containing the DNA-lipid complexes were removed after 3 h and replaced with complete  
growth media, and cells were harvested after 24 h.  
Cells were harvested in 1% NP-40 lysis buffer containing10 µg/ml leupeptin,  10 µg/ml aprotinin, 
100 µg/ml 4-(2-aminoethyl)benzenesulfonyl fluoride and centrifuged at 13,000 x g to clear the 
lysates. Protein content was determined by the Bradford method.  Total cell lysates (20 µg 
protein) were resolved by SDS-PAGE and transferred to nitrocellulose membranes (Schleicher & 
Schuell). Membranes were incubated in 5% milk (BioRad), 1% IgG free bovine serum albumin 
(BSA) (Sigma) blocking solution and probed with primary antibodies overnight at 4° C. Positive 
antibody reactions were visualized using peroxidase-conjugated secondary antibodies and an 
2.11 Transfections 
2.12 Western blot 
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enhanced chemiluminescence detection system (Renaissance, Perkin-Elmer Life Sciences) 
according to the manufacturer's instructions.  Affinity purified anti-b-tubulin (Cedarlane, 
Hornby, Ontario) was used as a loading control for the Western blots.  Protein expression levels 
were quantified as described for Northern blots. 
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The papain superfamily neutral cysteine protease BLMH has been genetically associated with 
increased risk for Alzheimer’s disease (AD) (Montoya et al., 1998; Papassotiropoulos et al., 
2000) and shown to alter the processing of the amyloid precursor protein (APP) when ectopically 
overexpressed (Lefterov et al., 2000; Lefterov et al., 2001).  Despite these observations, the 
distribution of BLMH and physiological functions within the CNS are unknown. 
Papain superfamily cysteine proteases are ubiquitous proteases that function not only in 
general protein degradation but also have roles linked to specific biological processes important 
for both normal physiology and disease.  In the CNS, calcium dependent calpains are activated 
following excitotoxic and ischemic insults and are implicated in neurodegeneration by their 
ability to cleave a small targeted set of proteins such as the cytoskeletal protein spectrin and the 
Ca2+/calmodulin dependent phosphatase calcineurin (Nixon et al., 1994, Chan et al., 1999; Wang 
et al., 2000; Wu et al., 2004).  These proteases are also believed to play roles in signal 
transduction and possibly synaptic plasticity (Hell et al., 1996; Wechsler et al., 1998; Chan et al., 
1999; Sato et al., 2001).  Another member of the papain superfamily, cathepsin L has recently 
been shown to be responsible for converting proenkephalin to the active enkephalin peptide 
neurotransmitter (Yasothornsrikul et al., 2003).  Active enkephalin is involved in regulation of 
analgesia, behavior and immune cell functions.  In cathepsin L knockout mice, active enkephalin 
levels are significantly reduced and precursor levels are relatively increased (Yasothornsrikul et 
al., 2003). 
AD is a devastating age associated progressive neurodegenerative disease characterized 
by cognitive decline, deposition of APP protein derived Ab  peptide in extracellular amyloid 
3 EVALUATION OF THE CNS IN THE BLMH NULL MOUSE 
3.1 Introduction 
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plaques, intraneuronal neurofibrillary tangles and neuronal loss.  Age is the single largest 
predictive factor for the onset of sporadic AD, and the occurrence of dementia, of which AD is 
the most common cause, rises exponentially with age (Jorm et al., 1987, Rocca et al., 1991).  
Although they fail to fully replicate the human disease, mouse models of AD have proven useful 
for understanding some aspects of the molecular pathology of the disease (Duff and Rao, 2001; 
Janus and Westaway, 2001; Dodart, 2002).  In addition, normal age related changes in rodents 
such as changes in locomotion and spacial memory cognitive declines may parallel aging in 
humans (Janicke et al., 1983; Gower et al., 1993; Ingram and Jucker, 1999; Frick et al., 2000) 
In the following studies, effects in the CNS of the targeted deletion of Blmh in mice were 
evaluated by immunohistochemistry and behavioral phenotyping.  Male and female young and 
aged animals were evaluated to access changes related to aging in Blmh null mice.  Deletion of 
Blmh was shown to result in increased astrogliosis and decreases water maze probe trial 
performance suggesting that Blmh may have specific and non-redundant functions in the CNS. 
 
The expression and distribution of Blmh in the murine CNS homogenates was determined from 
snap frozen microscopically dissected brain tissues.  Blmh protein was found to be present in all 
regions of the brain surveyed by Western blotting.  Relatively little variation in protein levels 
were noted among the regions surveyed (Figure 1).   
3.2 Results 
3.2.1 Distribution of Blmh in the murine CNS 
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Figure 1 Murine Blmh is expressed throughout the CNS. 
Murine brain tissues from (A) hippocampus, (B) cerebral cortex, (C) medial septum, (D) brain 
stem and (E) cerebellum from wild type (+/+) and Blmh null (-/-) mice were microscopically 
dissected and snap frozen.  Tissue was then homogenized, run on sodium dodecyl sulphate-
polyacrilamide gel electrophoresis (SDS PAGE) and probed by Western blot analysis for Blmh 
with rabbit anti-rat antibody, and then reprobed with anti-b-tubulin as a loading control. 
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Brains of twenty month old male B6.129 Blmhtm1Geh/J null and littermate wild type mice were 
stained with Nissl to detect cell bodies, probed for glial fibrillary acidic protein (GFAP) to 
identify astrocytes, and for an antigen associated with the complement C3bi receptor (OX42) to 
identify microglia.  Blmh null mice and wild type littermate controls were similar in gross 
appearance of the CNS and Nissl staining (Figure 2).  Immunostaining for GFAP revealed that 
the aged null animals had marked global astrogliosis in comparison to their wild type littermates 
(Figure 3 A-D).  The GFAP stained cells in the null brains appeared hypertrophied and were 
poorly organized in comparison to those in the brains of the wild type littermates. No obvious 
significant differences in staining for OX42 were noted between wild type and null animals (data 
not shown). 
3.2.2 Immunohistochemistry  
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Figure 2 Nissl staining of B6.129 Blmhtm1Geh/J hippocampus 
Serially sectioned 4 % paraformaldehyde fixed brain tissue from littermate aged wild type and 
Blmh null B6.129 Blmhtm1Geh/J mice were stained with Nissl. Representative Nissl staining of the 
hippocampus (n=3 +/+, -/-)(10x).  Bar represents 100 microns.   
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Figure 3 GFAP staining of B6.129 Blmhtm1Geh/J hippocampus  
Serially sectioned 4 % paraformaldehyde fixed brain tissue from littermate aged wild type and 
Blmh null B6.129 Blmhtm1Geh/J mice were immunostained with GFAP to detect astrocytes. 
Representative GFAP staining of A.  CA 1 region of hippocampus (10x), B. CA 1 region of 
hippocampus (40X), C.  CA3 region of hippocampus (10x), D. CA3 region of hippocampus 
(40x) (n=3 +/+, -/-). 
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Littermate hybrid Blmh null, heterozygote and wild type mice were bred in accordance with the 
recommendations of the Banbury Conference (Banbury Conference, 1997) to standardize genetic 
background.  Phenotypes of ‘knock-out’ mice by homologous recombination can vary 
significantly due to genetic background and the presence of unknown genetic modifiers (Owen et 
al., 1997; Ingram et al., 1999; Magara et al., 1999; Royle et al., 1999).  Although targeted 
deletions are maintained in inbred strains of mice, these are generally poor subjects for 
behavioral analysis and other phenotypic characterization due to abnormalities present in the 
parental strains (Banbury Conference, 1997).  Hybrid crosses may eliminate the homozygosity of 
alleles that complicate the characterization of targeted deletions in inbred strains (Banbury 
Conference, 1997).  In addition, 129B6 F1 hybrid animals in particular have been shown to 
outperform many inbred strains in the Morris water maze and contextual fear conditioning 
(Owen et al., 1997).  
Genotype distribution of the F1 hybrids did not deviate from the expected Mendelian 
ratio (c2 = 4.62, P > 0.10) (Table 2).  Null animals often appeared smaller at weaning, but were 
otherwise indistinguishable in gross appearance from heterozygote and wild type littermates.  
Body weight at 4-5 months was significantly smaller for null animals (-/- = 30.8 + 0.7 g, n = 7; 
+/+  = 35.9  + 0.9 g, n = 8; P < 0.005, two-tailed t-test) but this difference did not persist in 
animals older than 14 months (aged males, 42.2 + 1.8 g; aged females 42.2 + 1.5 g) and no 
significant differences were noted among genotypes in the older animals (males, P = 0.14; 
females, P = 0.10).  In the isogenic 129S6-Blmhtm1Geh/J and the congenic B6.129Blmhtm1Geh/J 
background, the Blmh targeted deletion resulted in an unusual tail dermatopathology (Schwartz 
et al., 1999) that was not observed in any of the hybrid mice.   
3.2.3 [129S6-Blmhtm1Geh/J X B6.129 Blmhtm1Geh/J]F1 hybrid animals 
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Table 2 Genotype distribution of Blmh F1 hybrids. 
 
+/+ +/- -/- 
   
 
Observed 
Male 
Observed 
44 
Expected* 
31 
Observed 
56 
Expected* 
63 26 
Expected* 
32 
Female 35 30 61 61 26 31 
Total 79 62 117 124 52 62 
 
*expected number of animals assuming a 1:2:1 Mendelian distribution 
 43 
 
Motor coordination and balance were assessed for null and wild type young and aged [129S6-
Blmhtm1Geh/J X B6.129 Blmhtm1Geh/J]F1 hybrid animals mice by rotarod testing.  Time spent on 
the apparatus reported as latency to fall from the rotarod apparatus was measured in seconds and 
assessed for each animal during each day of testing.  At 4-5 months, the performance of both 
wild type and null male mice significantly improved over the 7 day trial period as noted by the 
increased time spent on the rotarod over consecutive days (repeat measures ANOVA, F(6,78) = 
41.0, P<0.0005) and did not vary between the genotypes (F(1,13) = 1.9, P = 0.19) (Figure 4A).  
Retesting of the same group of male animals at 14-15 months again showed significant 
improvement over the trial period (F(6,72) = 3.9, P < 0.005), but surprisingly, significant 
differences emerged between genotypes (F(1,12)=6.3, P<0.05) (Figure 4B). 
  Naïve aged female mice (20-23 months) were evaluated to determine if the differences 
seen between genotypes in aged males were related to previous rotarod testing.  Significant 
improvement in performance was observed over the trial days (F(5,50) = 4.6, P < 0.005) and 
significant differences were noted between genotypes (F(1,10) = 17.1, P < 0.005) (Figure 4C).  
Post hoc tests showed that the aged female null mice had significantly longer latency to fall than 
wild type controls on days 1-4 of testing.  Overall performance of aged males and females did 
not differ (F(1,52) = 0.8, P = 0.37) indicating that the observed difference in performance was 
independent of previous rotarod exposure.   
3.2.4 Rotarod test 
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Figure 4  Rotarod testing of Blmh null F1 hybrids.    
Young and aged F1 hybrid Blmh wild type and null mice were tested over seven days on an 
accelerating roratod apparatus (3-19 rpm).  Latency to fall from the apparatus was measured for 
each animal during each 180 s trial and represented as mean for each genotype + SEM. A.  Seven 
day accelerating rotarod test for 4-5 month old young males (+/+ n = 8, -/-n = 7).  B.  Seven day 
accelerating rotarod retesting for males at 14-15 months (+/+ n = 7, -/- n = 7).  C.  Seven day 
accelerating rotarod test for naïve aged 20-23 month females (+/+ n = 6, -/- n = 6).   * Post hoc 
test P< 0.05. 
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Spontaneous exploratory behavior and locomotion were tested using the open field format.  No 
differences between genotypes were observed for any of the parameters tested in any of the 
groups of animals evaluated  (Table 3).  Rearing behavior was significantly different between 
pooled young (4-6 months) and aged mice (20-23 months) (P<0.05, t-test); otherwise, young and 
aged animals performed similarly. 
3.2.5 Open field test 
 47 
 
Table 3 Open field testing of Blmh null F1 hybrids. 
Young and aged F1 hybrid Blmh wild type and null mice were individually evaluated for 10 min 
in an open field apparatus.  The velocity, distance, location and duration of travel bouts, rearing 
and occurrence of stereotypical behavior were recorded and represented in the table as mean + 
SEM.  Rearing behavior differed significantly between pooled young and aged mice. * P< 0.05. 
 
 YOUNG MICE AGED MICE 
 +/+ (n=15) -/- (n=18) +/+ (n=12) -/- (n=10) 
Velocity (cm/s) 34.4 +  1.5 31.8 +  0.9 33.4 +  2.0 33.8 +  2.9 
Time traveled (s) 41.9 +  3.8 45.1 +  4.5 32.6 +  7.1 43.4 +  8.2 
Time at rest (s) 468.2 +  7.0 462.9 +  7.4 477.3 +  14.5 471.5 + 13.6 
Stereotypical behavior (s) 83.2 +  3.1 85.2 +  3.4 79.3 +  5.6 83.7 +  6.4 
Rearing (s)* 22.8 +  4.9 16.0 +  3.0 10.0 +  3.6 9.9 +  4.0 
Percent time in center 14.4 + 3.3 10.5 +  1.8 14.7 +  4.4 16.6 +  7.4 
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In the contextual fear conditioning paradigm, both young and aged mice displayed significant 
conditioning to context and tone (young animals, F(5,170) = 116.6, P < 0.0001; aged animals, 
F(5,125) = 60, P < 0.0001). No significant differences due to genotype were observed for either 
group of pooled animals (young animals, F(1,34) = 1.3, P = 0.26; aged animals F(1,25) = 0.8, P 
= 0.37) or for any of the individually tested groups.  In comparison to young animals, aged 
animals were found to display a higher degree of fear as indicated by freezing behavior in the 
contextual fear test (F(1,61) = 77.5, P < 0.0001) (young animals +/+ n  =  17, -/- n  =  19; aged 
animals +/+ n  = 14, -/- n  =  13) (Figure 5).  Post-hoc testing revealed the aged animals 
displayed increased fear in all aspects of contextual fear conditioning compared to young 
animals. 
 Animals were also tested in a light-dark box to assess anxiety as indicated by increased 
time spent in darkness.  No differences were noted between genotypes in percent time spent in 
light for either young (young males:  -/- = 11.7 + 3.4, n = 8, +/+ = 9.9 + 3.2, n = 7; P = 0.71) or 
aged males (aged males: -/- = 31.2 + 11.7, n = 6, +/+ = 33.3 + 14.2, n = 8; P = 0.92).  Young and 
aged males did however significantly differ in the percentage of time spent in the light (young = 
10.9 + 2.3 n = 15, aged = 32.4 + 10.0 n = 14; P < 0.05). 
3.2.6 Contextual fear conditioning 
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Figure 5 Contextual fear conditioning of Blmh null F1 hybrids. 
Contextual fear conditioning was evaluated in young and aged F1 hybrid Blmh wild type and 
null mice.  On the first day of testing, animals were exposed for 2 min to a cued context (train-
context) and a 30 s tone (train – tone).  During the last 2 s of the tone, the animals received a 
0.75 mA foot shock.  Tone and shock pairing was repeated once after 2 min.  Twenty four hours 
later, the animals were evaluated for freezing when exposed to the original cued context 
(context) or when exposed to the tone in a novel context (tone).  Data are represented as 
genotype mean + SEM.  Aged animals showed significantly more freezing than young animals in 
all components of the test (**P < 0.0001)
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A hot plate test was conducted to evaluate the animals ability to sense uncomfortable stimuli.  
Latency to paw lick, shake and jumping was evaluated as a measure of pain. In the hot plate test, 
young wild type animals showed a decreased latency to front paw lick in comparison to nulls 
(P<0.0005, t-test) (Table 4).  In fact, in all the parameters tested in the hot plate test, the young 
null animals showed a tendency toward increased latency that did not reach statistical 
significance. Aged animals showed a decreased latency for hind shake compared to young 
animals (P<0.05, t-test).  No significant differences in latency to front paw lick, hind paw lick or 
jump were observed between young and aged mice. 
3.2.7 Hot plate test 
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Table 4 Hot plate testing for Blmh null F1 hybrids.    
Latency to behaviors reflecting pain sensation were recorded for young and aged F1 hybrid Blmh 
wild type and null mice during the hot plate test.  Times are noted as the mean + SEM.  * P< 
0.0005. 
 
 
 
 Young mice Aged mice 
 +/+ n=17 -/- n=19 +/+ n=13 -/- n=13 
Latency to front lick (s) 14.4 + 0.6* 18.8 + 0.9* 15.2 + 1.3 15.4 + 2.6 
Latency to hind lick (s) 29.6 + 2.2 36.6 + 2.7 33.5 + 6.9 24.4 + 1.9 
Latency to hind shake (s) 26.4 + 1.5 32.2 + 2.5 21.1 + 2.0 21.5 + 2.0 
Latency to jump (s) 162.6 + 12.7 199.7 + 14.6 170.8 + 20.0 222.3 + 20.1 
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The ability of mice to acquire and recall spatial information was assessed by escape latency from 
the Morris water maze over a five day testing period.  The testing period was followed by two 
days of visual acuity testing using the water maze with the platform made plainly visible above 
the water surface.  The first group of young male animals tested differed significantly in overall 
performance from the other two groups of young animals in water maze acquisition results as 
well as swim speed and thus was not included in the pooled data (data not shown).   
Groups of male and female young and aged animals individually displayed significantly 
improved performance over the trial period as indicated by the decreased escape latencies over 
consecutive days. Performance did not differ by genotype in any of the groups tested. No 
significant differences were observed for gender in the young or aged animals; thus, the males 
and females were pooled.  Pooled data also revealed significant improvement in escape latency 
over the trial period (young animals, F(6,138) = 31.9, P < 0.0005; aged animals, F(6,120)=34.1, 
P<0.0005; repeat measures ANOVA). Water maze acquisition and visible platform testing did 
not differ between genotypes for either pooled young (F(1,23) = 3.2, P = 0.09) or aged animals 
(F (1,20) = 2.3, P = 0.14) (Figure 6 A and B).   
3.2.8 Water maze test 
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Figure 6  Water maze testing - acquisition  
 
 
Young and aged F1 hybrid Blmh wild type and null animals were evaluated for learning and 
vision by water maze testing.  On days 1-5, each animal received four 120 s training trials in 
which the animal was allowed to swim freely about a pool where a submerged hidden platform 
was located.  On days 6 and 7, the same testing procedure was repeated with the platform made 
visible.  Latency to escape from the water was measured for each animal in s and represented as 
mean + SEM.  A.  Water maze testing for pooled male and female young animals (+/+ n = 12, -/- 
n = 13). B.  Water maze testing for pooled male and female aged animals (+/+ n=10, -/- n=12). 
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After the five days of the acquisition or learning phase of the water maze testing, each 
animal was evaluated for retention of the submerged platform location by probe trial testing.  
The platform was removed from the water tank and each mouse was evaluated for 60 s for the 
amount of time spent in each of the quadrants of the tank.  Memory of the platform location is 
indicated by percent time spent in the target quadrant.  If an animal shows no prefence for the 
quadrant target over the other three quadrants, this animal would be expected to spend at least 25 
% of the probe trial in the target quadrant as a function of chance.   
In the probe trials tests, young null animals spent significantly less time in the target 
quadrant than littermate controls, but still preferred the target quadrant above the other quadrants 
(+/+ n = 12, -/- n = 13, P<0.05) (Figure 7A).  This difference was also independently observed in 
the first group of young males tested (+/+ n = 5, -/- n = 6, P < 0.05) (data not shown).  Aged wild 
type and null mice did not display differences in probe trial performance (+/+ n = 10, -/- n = 12, 
P=0.54) (Figure 7B).  Swim speeds did not differ by genotype within groups; however, aged 
animals swam significantly slower than young animals (young +/+ = 22.25 + 0.43 cm/s; aged 
+/+ = 18.72 + 1.05 cm/s, P = 0.0034).  Overall, young wild type animals tended to perform better 
in the probe trial than aged controls, but the trend did not reach significance (pooled young +/+ 
percent time in target = 47.07 + 2.65 %, pooled aged +/+ = 38.88 + 3.68 %, P = 0.08). 
 56 
 
 
 
                                 
tar
ge
t
co
ntr
ol 1
con
tro
l 2
con
trol
 3
targ
et
con
tro
l 1
co
ntr
ol 2
con
tro
l 3
0
10
20
30
40
50
60
70
+/+
-/-
P
er
ce
nt
 t
im
e
+/+ -/-
     **
tar
ge
t
co
ntr
ol 1
con
tro
l 2
con
trol
 3
targ
et
co
ntr
ol 1
con
tro
l 2
con
tro
l 3
0
10
20
30
40
50
60
70
+/+
-/-
P
er
ce
nt
 t
im
e
+/+ -/-
 
A. B. 
 
 
Figure 7  Water maze testing - probe trials.   
 
Probes trials were conducted to evaluate retention of the submerged platform location after the 5 
days of acquisition training.  Young and aged F1 hybrid Blmh wild type and null animals were 
allowed to swim freely for 60 s in the water tank with the platform removed.  Time spent in each 
quadrant was recorded.  Target quadrant represents the quadrant that formerly contained the 
submerged platform.  Young null males performed significantly differently than wild type 
controls. A. Probe trial testing for pooled young male and female mice. B. Probe trial testing for 
pooled aged male and female animals.   
** P<0.05   
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Significant differences were observed between animals lacking the Blmh gene and littermate 
controls in both brain immunohistochemistry and a complex spatial memory dependent 
behavioral task.  Immunohistochemical analysis revealed an increased presence of GFAP stained 
astroglia in the brains of aged null mice.  In the water maze probe trials, an indicator of memory 
retention, young null animals displayed less recollection of the target quadrant than controls. 
These data suggest a non-redundant physiological role for Blmh in the CNS. 
 Studies characterizing targeted deletions can be confounded by gene redundancy, 
compensation of lost activity by other functionally similar proteins, genotypic influence of 
genetic background, disruption or modification of neighboring genes and unintended 
consequences of expression of selection markers (Bockamp et al., 2002).  Although Blmh is a 
single copy gene, some phenotypic features of the Blmh knockout may be masked by activity of 
other functionally similar cytosolic aminopeptidases.  F1 hybrids generated from backcrossed 
isogenic 129S6-Blmhtm1Geh/J and congenic B6.129Blmhtm1Geh/J may represent a better 
background for studing the null mutation than inbred strains, but generation of F1 hybrid animals 
is both time consuming and expensive. F1 hybrids also do not overcome the problems associated 
with flanking genes (Wolfer et al., 2002).  For genes linked to the targeted deletion, linkage 
disequilibrium will exist between the null mutation and flanking sequences that are derived from 
substrains of 129 inbred mice.  These studies cannot rule out the observed phenotypic effects 
3.3 Conclusions 
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being related to flanking genes, disruption or modification of neighboring genes or expression of 
the neomycin selection marker rather than disruption of the Blmh gene.    
    
 
Immunohistochemical evaluation of the CNS of aged B6.129 Blmhtm1Geh/J wild and null animals 
revealed significant global astrogliosis as indicated by increased GFAP staining in null animals, 
but no obvious differences in the staining for OX42, an activated microglial marker.  It is unclear 
if the increased GFAP staining observed in the null mice resulted in increased proliferation 
and/or simply the activation and hypertrophy of existing astroglial cells. GFAP is the major 
intermediate filament in astrocytes and also a specific marker for mature astrocytes (Eng et al, 
1971; Eng and Ghirnikar, 1985).  The protein is augmented in aging and also in response to all 
types of CNS injury and changes in neuronal-glial interactions that underlie the astrocyte’s 
primary role in the maintenance of the neural microenvironment (Bjorklund et al., 1985; 
Newcombe et al., 1986; Hansen et al., 1987; Steward et al., 1991).  Global astrogliosis is found 
in targeted deletions such as the neurofibromatosis type 1 null (Zhu et al., 2001).  Astrogliosis is 
also observed in disease of the human CNS including AIDS dementia, prion associated 
spongiform encephalopathies and neurodegenerative disease such as Alzheimer’s disease and is 
believed to indicate neuronal injury or dysfunction (Eng and Ghirnikar, 1994).  The role of 
astrogliosis in promoting neuronal healing after injury or disease remains unclear (Ridet et al., 
1997; McGraw et al., 2001). A glial scar produced by astrocytosis may be an attempt to isolate 
an injured area with resulting limited capability for neuronal axon regeneration (Ridet et al., 
3.3.1 Astrogliosis  
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1997; McGraw et al., 2001).  Alternatively, astrogliosis may play an important role in providing 
a healing environment for the injured neuron (Janzer and Raff, 1987; Bush et al., 1999; John et 
al., 2004).  The observation that expression of the microglial marker OX42 is not increased in 
aged Blmh null animals indicates that the pathology present in the brains of the null mice at the 
time of examination did not appear to have a significant inflammatory component.  Although 
Blmh null mice did not appear to have any gross neuronal loss, neuronal injury and subtle loss, 
or neuronal dysfunction may be present accounting for the observed astrogliosis. 
 
 
In three independently tested groups of young F1 hybrid [129S6-Blmhtm1Geh/J X B6.129 
Blmhtm1Geh/J] animals, deletion of Blmh resulted in a modest, but statistically significant decrease 
in target quadrant retention in the water maze probe trial.  These differences were not accounted 
for by diminished locomotor activity or visual impairment as evidenced by the performance of 
the young null animals in the rotatod, open field and water maze visible platform tests.  In 
addition, young null animals did not differ significantly in swim speed from wild type controls; 
however, subtle differences in sensory and motor function cannot be ruled out.  
  Aged wild type and null animals performed similarly in learning and memory tasks 
including the water maze acquisition and probe trials, and contextual fear conditioning.  The lack 
of a significant difference in probe trial results between aged null and wild type mice is probably 
due to a small decline in the performance of the wild type animals with age. Age related decline 
in complex learning tasks such as the Morris water maze are well documented in multiple strains 
3.3.2 Behavioral phenotype of F1 hybrids 
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of mice (Gower et al., 1993; Frick et al., 2000; Magnusson et al., 2003).  Non-cognitive 
impairment does not appear to account for these changes.  Although both water maze and 
contextual fear conditioning learning and memory are believed to be mediated by hippocampal 
dependent components, lack of correlated findings in the two paradigms may reflect significant 
differences in the biology underlying learning in these tasks (Owen et al., 1997).  Data from 
lesion studies has shown that the degree of hippocampal dependency for water maze and 
contextual fear conditioning differs and implies that different pathways may be involved in 
learning these tasks (Logue et al., 1997). 
 The aged Blmh null mice unexpectedly displayed an increased latency to fall from the 
rotarod in comparison to wild type controls irrespective of prior exposure to the task.  Similar 
differences between null and wild type animals were observed in the 129S6-Blmhtm1Geh/J 
background (D. Schwartz, personal communication).  Other rodent studies have noted age 
related declines in complex motor tasks including rotarod (Janicke et al., 1983; Shukitt-Hale et 
al., 1998).  The observed results may reflect a combination of significantly larger size of the aged 
animals compared to the younger animals (P<0.0005) and a perhaps a greater decline in strength 
or other parameters affecting locomotor ability and or balance in wild type animals. The role of 
BLMH in the neuromuscular system is uncharacterized.   The related calpain proteases have 
significant functions in the neuromuscular system; for example, loss of function genetic 
mutations in calpain 3 have been identified as the cause of limb-girdle muscular dystrophy 2A 
(Huang et al., 2001).   
 Although having a lower body weight in the first few months of life than wild type 
controls, [129S6-Blmhtm1Geh/J X B6.129 Blmhtm1Geh/J] knockout animals did not display neonatal 
mortality and dermatopathology observed in the inbred stains with Blmh deletion (Schwartz et 
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al., 1999).  It is unknown if the hybrid animals are more resistant to the dermal pathology or if 
environmental conditions that induce this pathology (Schwartz et al., 1999) were lacking for the 
duration of the hybrid studies.  Overall, the F1 hybrid animals performed well in all behavioral 
paradigms evaluated consistent with reports of overall hybrid vigor (Owen et al., 1997) and 
represent a well defined background for the characterization of the Blmh deletion. 
 Aging is a dynamic process and age related behavioral changes do not necessarily 
correlate linearily with chronological age.  In addition, age related changes in rodents display a 
significant amount of individual variability (Doyere et al., 2000). Age related changes occur as a 
function of strain (Lhotellier et al, 1989; Ingram et al., 1999) and this study provides baseline 
data on behavioral changes with aging in the F1 hybrid background.  Overall few significant 
changes were noted between young and aged animals with the most notable difference being the 
increase in generalized freezing, an expression of fear, in aged mice in contextual fear 
conditioning.  Similar results were noted for aged 22 month old vs 7 month old Winstar rats 
(Doyere et al., 2000).  Other studies have reported significant declines in contextual conditioning 
in aged rodents observed only with repeated presentation of the context or tone over time (Ward 
et al., 1999; Houston et al., 1999).  The reason for the increased freezing in the aged animals is 
not known and did not appear to be caused by overall greater anxiety levels as aged animals 
spent more time in the lighted section of the light-dark box than young animals. 
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Molecular genetic studies have indicated a possible role for the papain superfamily cysteine 
protease BLMH in neurodegenerative disease.  Genetic association studies have reported BLMH 
as a susceptibility locus for AD based on the genotype distribution of a single nucleotide 
polymorphism (SNP) that results in a conserved I443V substitution (Montoya et al., 1998; 
Papassotiropoulos et al., 2000).  Genotyping of the same SNP has also shown BLMH to exhibit 
modest transmission disequilibrium with autism  (Kim et al., 2002).  Although the polymorphism 
is in the conserved BLMH C-terminus which functions in regulation of the enzymatic activity 
(Zheng et al., 1998), the physiological importance of the I443V substitution is unknown.  The 
location of the functionally significant locus could be the conserved C-terminal SNP or 
alternatively, another linked locus within BLMH or a neighboring gene. 
Preliminary examination of promoter regions of papain family cysteine proteases reveals 
the lack of a classical TATA box and constitutive expression mediated in part by GC rich Sp1 
binding sites (Hata et al., 1989; Azizkhan et al., 1993; Shi et al., 1994; Phillipsen et al., 1999; 
Jean et al., 2002; Yan et al., 2003).  Despite the appearance of having a housekeeping gene 
promoter, transcriptional regulation among the papain superfamily members is an important 
control mechanism as highlighted by the focal expression pattern and transcriptional induction of 
some of the cathepsins and calpains (Shi et al., 1994; Rantakokko et al., 1996; Storm van's 
Gravesande, 2002). 
Like other papain superfamily members, the cloned upstream region of BLMH lacks 
common consensus transcriptional regulatory elements, such as a TATA box or CCAAT box and 
contains several consensus Sp1 binding sites (Ferrando et al, 1997).  The putative promoter 
4 EVALUATION OF THE BLMH TRINUCLEOTIDE REPEAT POLYMORPHISM 
 
4.1 Introduction 
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region of human BLMH also contains a polymorphic trinucleotide repeat –134 bp upstream the 
ATG start site (Ferrando et al., 1997).  The impact of this polymorphic site on BLMH 
transcription is unknown, however the polymorphism lies near a highly conserved region of the 
5‘untranslated region that contains several putative Sp1 binding sites and an AP1 consensus site.  
Polymorphic trinucleotide repeats in the 5’ untranslated regions of other genes have been found 
associated with neurological disease for example X-linked mental retardation results from 
hyperexpansion of a CCG repeat in the 5’ untranslated region (UTR) of FMR2 (Gu et al., 1996; 
Gecz et al. 1996).  In addition, small insertions and deletions in putative promoter regions have 
been shown to be associated with and even cause altered gene expression (Boniotto et al., 1996; 
Ye et al., 2001).  In the human stromelysin 1 gene a single adenosine insertion/deletion results in 
a run of either 5 or 6 adenosine nucleotides in the 5’untranslated region and is found to mediate 
differential expression of this gene as shown using a chloramphenicol acetyltransferace reporter 
assay (Ye et al., 1996).    
In the following studies, two additional polymorphic sites in the BLMH were identified from 
a polymorphism screen of the BLMH 5’ putative proximal promoter and exonic regions.  In 
addition, the trinucleotide repeat polymorphism was found not to affect basal transcription from 
the proximal promoter based on results of a luciferace reporter assay system.  These finding are 
discussed in the context of the genetic association of BLMH with AD. 
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5’RACE analysis of murine RNA derived from cerebral cortex revealed two transcriptional start 
locations at –104 bp (numbering based on human gene) and –53 bp from the ATG start site.  
This area of the murine 5’ untranslated region has 62 % identity with the human gene.  The 
murine transcriptional start site also lies adjacent to a region of DNA from –179 to –279 that is 
highly conserved with 97 % identity to the human gene. 
All twelve exons with their flanking intronic regions and 1.2 kb of the putative proximal 
promoter were screened for polymorphisms using SSCP and direct cycle sequencing of genomic 
DNA amplified by PCR from the Pittsburgh Alzheimer’s Disease Research Center (ADRC) 
autopsy confirmed cases (n = 10) and controls (n = 10).  The screen identified two novel 
polymorphic sites. A silent C602G polymorphism was found in exon 6 by differential pattern of 
migration on the SSCP gel and confirmed by direct cycle sequencing. A CA repeat 
polymorphism was found at –1156 by direct cycle sequencing with (CA)7 and (CA)8 observed in 
the screened population (Figure 8).  Both mutations were observed in both AD cases and 
controls. 
 
 
 
 
4.2 Results 
4.2.1 5’ RACE and polymorphism screen of the BLMH gene and 5’ upstream region 
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Figure 8 Polymorphic sites in the BLMH gene  
 
PCR amplicons from each of the BLMH gene exons and flanking 5’untranslated region from AD 
cases (n = 10) and aged matched controls (n = 10) from the Pittsburgh ADRC were screened by 
SSCP and direct cycle sequencing for polymorphic sites.  Four polymorphic sites were 
identified.  A novel (CA)n was observed at –1156 from the ATG start site by SSCP and a novel 
G602C SNP was seen in the sixth exon.  A previously described trinucleotide repeat (CCG)n in 
the proximal promoter (Ferrando et al., 1997) and the A1326G polymorphism (Bromme et al., 
1996) were also observed. 
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To evaluate the role of the -134 (CCG)n trinucleotide repeat polymorphism in the basal 
transcription of BLMH, 1.2 kb of the 5’ untranslated region containing either the (CCG)9 or 
(CCG)10 polymorphic variants were cloned from human genomic DNA into the pGL3 basic 
luciferase reporter vector (Promega).  Seven to eleven repeats were observed in a Caucasian 
population of 116 individuals with the allele frequencies of 0.621 for (CCG)9, 0.362 for (CCG)10 
and less than 0.05 for the (CCG)7 and  (CCG)11 alleles which were not cloned. Two cells lines, 
HEK 293 cells and SH-SY5Y neuroblastoma cells, were selected for these assays due being 
derived from human tissues, with SH-SY5Y cells being brain derived.  Ease of transfection also 
contributed to the selection process.  Both cell lines also endogenously express BLMH.  
Luminescence assays from firefly and renilla luciferase were linear over a 10X dilution of 
transfected cell lysate and no detectable cross over of signal was seen between the firefly and 
renilla luciferase (Figure 9 A, B and C).  The cloned 1.2 kb 5’untranslated region was found to 
function effectively as a promoter in the luciferase construct in both cell lines.  No significant 
differences in basal transcription from the (CCG)9 and (CCG)10 pGL3 constructs were observed 
for either the HEK 293 ( P = 0.92), or SH-SY5Y cells (P = 0.06) (Figure 9 D and E). 
4.2.2 pGL3 5’BLMH luciferase reporter assays 
 67 
 
A. 
0.00 0.25 0.50 0.75 1.00 1.25
0
20000
40000
60000
293 pGL3 control
SH-SY5Y pGL3 control
293 pRL TK
SH-SY5Y pRL TK
Relative concentration of DNA
Lu
m
in
es
ce
nc
e
 
B. 
pG
L3
 co
ntr
ol
pG
L3
 ba
sic
pR
L T
K
pG
L3
 co
ntr
ol p
RL
pG
L3
 ba
sic
 pR
L
0
20000
40000
60000
293
Lu
m
in
es
ce
nc
e
 
 
 
 
 68 
 
C.  
pG
L3
 co
ntr
ol
pG
L3
 ba
sic
pR
L T
K
pG
L3
 co
ntr
ol p
RL
pG
L3
 ba
sic 
pR
L
0
20000
40000
60000
SHSY5Y
Lu
m
in
es
ce
nc
e
 
 
 
D. 
pG
L3
 co
ntr
ol
pG
L3
 ba
sic
un
tra
ns
fec
ted
pG
L3
 (C
CG
)10
pG
L3
 (C
CG
)9
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
lu
m
in
es
ce
nc
e
 
 
 
 69 
 
E. 
pG
L3
 co
ntr
ol
pG
L3
 ba
sic
un
tra
ns
fec
ted
pG
L3
 (C
CG
)10
pG
L3
 (C
CG
)9
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
lu
m
in
es
ce
nc
e
 
Figure 9 Luciferase reporter assay for BLMH trinucleotide repeat polymorphism 
Luminescence from a luciferase reporter construct driven by 1.2 kb of the 5’ untranslated region 
of BLMH containing a polymorphic trinucleotide repeat was measured in HEK 293 and SH-
SY5Y cells.  Linearity of the assay was determined by serial dilutions of either cell lysates 
transfected with the pGL3 control vector containing SV40 promoter elements or pRL TK renilla 
vector driven by the thymide kinase promoter.  Firefly luciferase or renilla luciferase crossover 
was assayed by single transfections with each of the vectors and compared to the reporter assay 
dual transfection with the pGL3 and pRL vectors. Data represent mean values and error bars 
show SEM from 3-6 independent experiments. A.  Linearity of assay. B. Control plasmid 
expression in HEK 293 C. Control plasmid expression in SH-SY5Y. D.  HEK 293 relative 
luminescence for (CCG)9 and (CCG)10  pGL3 constructs.  E.  SH-SY5Y relative luminescence for 
(CCG)9 and (CCG)10  pGL3 constructs. Luminescence for (CCG)9 and (CCG)10  pGL3 constructs
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were not statistically significantly different for either cell line based on analysis by t-test. 
 
BLMH was first associated with AD through genotyping at the A1326G loci in the twelfth exon 
(Montoya et al., 1998).  AD confirmed and clinical cases derived from the Pittsburgh ADRC and 
age matched controls from the same population were screened at the A1326G loci by SSCP of 
PCR amplicons of the twelfth exon derived from genomic DNA. The linked 5’(CCG)n repeat is 
located about 30 kb from the A1326 loci.  Pittsburgh ADRC cases and controls were amplified 
using PCR conditions as described by Ferrando et al. (1997) following 5’ 32P labeling of the 
forward primer. PCR products were electrophoresed on a 7% polyacrylamide gel and visualized 
by autoradiography.  When allele and genotype frequencies from the A1326G BLMH C-terminal 
SNP were compared with those from the –134 CCG repeat for Pittsburgh ADRC AD cases and 
controls, only the A1326G locus showed significant evidence of association with AD in the 
Pittsburgh ADRC population (Table 5).  Allele frequencies were not significantly differenct 
between cases and controls for neither the A1326G BLMH C-terminal SNP or the –134 CCG 
repeat.  Genotype frequencies for the G locus of the A1326G SNP was overrepresented in cases 
compared to controls (OR=2.28, 95% confidence interval = 1.02 to 5.00, C2 = 4.01, P < 0.05).  
Genotype frequencies were not significantly different for cases and controls for the – 134 CCG 
repeat (OR=1.43, 95% confidence interval = 0.74 to 2.80, C2 = 1.09, P not significant).  
 
 
 
4.2.3 Genetic association study revisited 
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Table 5 BLMH allele frequency and genotype distribution in AD cases and controls 
 
 
 
  TOTAL ALLELE FREQUENCY GENOTYPE FREQUENCY 
A1326G*   A G A/A A/G G/G 
 CASES 151 0.67 0.33 0.426 0.358 0.152 
 CONTROLS 124 0.70 0.30 0.468 0.460 0.073 
(CCG)n**   (CCG)9 (CCG)10 (CCG)9/(CCG)9 (CCG)9/(CCG)10 (CCG)10/(CCG)10 
 CASES 179 0.63 0.36 0.43 0.41 0.16 
 CONTROLS 116 0.62 0.36 0.38 0.46 0.13 
 
*A1326G allele and genotype distribution was previously published (Montoya et al., 1998) 
** Montoya, 1998 
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These studies focused on the trinucleotide repeat polymophism of the 5’ untranslated region of 
BLMH based on the proximity of the trinucleotide to the putative translational start site and 
conserved regions of the 5’ untranslated area.  Although no evidence for expansion of the 
trinucleotide repeat had been observed, 5’ untranslated region trinucleotide repeats may provide 
important spacing between elements of the promoter.  The calmodulin 1 gene has 7 CAG repeats 
(Toutenhoofd et al., 1998). Expansion of this trinucleotide to 20 or 45 repeats in a luciferase 
reporter construct does not alter transcriptional strength of the promoter, but complete deletion of 
the trinucleotide decreases the output of the promoter sequence by 45% (Toutenhoofd et al., 
1998).    
 The cloned 1.2 kb of the 5’ untranslated region contains sufficient active promoter 
elements to drive luciferase expression in both 293 and SH-SY5Y cells.  Basal transcription from 
the proximal promoter containing either the (CCG)9 or (CCG)10 allele was not significantly 
different.  These data do not eliminate the possibilities that the trinucleotide repeat could (1) 
differentially affect transcription from the intact promoter, (2) regulate transcription that is 
induced, or differentially regulate transcription in another untested cell type.  
When comparing the allele distributions of the Pittsburgh ADRC AD cases and controls 
at the A1326G SNP and trinucleotide repeat, association with AD was only observed with the 
A1326G SNP.   These observations suggest that the trinucleotide repeat polymorphism is not a 
significant functional locus in AD in the Caucasian Pittsburgh population studied.  It is 
4.3 Conclusions 
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interesting to note that in the linkage disequilibruim study of BLMH with autism, the 
trinucleotide repeat polymorphism locus was also found not significant (Kim et al., 2002).  Two 
additional novel polymorphisms were found in BLMH by polymorphism screening.  A C602G 
SNP that does not alter the amino acid usage and a CA repeat located –1156 bp from the ATG 
start site.  The allele distribution for the CA repeat polymorphism and C602G SNP remain to be 
determined in a normal population.  Further investigation may help determine if the functional 
locus for genetic association in AD and auatism is the same, and whether it lies within BLMH or 
another neighboring gene, such as the serotonin transporter gene, which is located about 15 kb 
downstream of BLMH A1326G. 
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MHC I epitopes are generated primarily through degradation of cellular proteins by the 
proteasome (Goldberg et al., 2002; Kessler et al., 2002).  Additional N-terminal trimming of 
peptides destined for MHC I presentation occurs through unidentified cytosolic aminopeptidases.  
MHC I epitope presentation can be modulated by stress proteins (heat shock) and stimulated by 
interferon gamma (INFg) (Fruh and Yang, 1999; Srivasta, 2002).  MHC I epitope presentation is 
important for immune system recognition of viruses and tumors as well as potentially having a 
function in neuronal development and synaptic plasticity (Huh et al., 2000).  
Cytosolic stress proteins are chaperones and constituents of the ubiquitin-proteasome system. 
These proteins participate in the transfer of candidate peptide epitopes into the endoplasmic 
reticulum for assembly onto MHC I molecules (Srivastava 2002).  In response to cellular 
stresses, the normal complement of cytosolic stress proteins are altered. For example, in the 
CNS, cytosolic stress protein composition can be altered by insults such as ischemia and trauma 
and is upregulated in some neurodegenerative diseases (Bonini, 2002; Yenari, 2002).   
Proteolytic processing both by the proteasome and putative N-terminal MHC I epitope 
processing aminopeptidases can be altered by INFg (Fruh and Yang, 1999; Kessler et al., 2002; 
Goldberg et al., 2002).  Exposure of cells to INFg can induce the replacement of the normal b 
subunits present in the proteasome by LMP2, LMP7 and MECL-1 (Gaczynska et al., 1993; Fruh 
et al., 1994).  INFg treatment also results in the induction of the 11S PA28a/b  subunits that can 
replace one or two of the 19S caps of the 26S proteasome (Groettrup et al., 1996).  Following 
5 BLMH INDUCTION BY INF g  
5.1 Introduction 
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treatment with INFg, the resulting modified proteasome assembly, the “immuno-proteasome”, 
displays altered proteolytic activity including stimulated cleavage after hydrophobic, basic and 
branched chain residues and diminished cleavage following acidic residues (Driscoll et al., 1993; 
Gaczynska et al., 1993; Aki et al., 1994).  The proposed N-terminal MHC I epitope processing 
aminopeptidases leucine aminopeptidase and ERAAP are also induced by INFg (Beninga et al., 
1998; Serwold et al., 2002).  BLMH is a candidate aminopeptidase for cytosolic MHC I  epitope 
processing (Stolze et al., 2000).  The protease was ident ified though its ability to produce correct 
sized peptides from putative protein substrates. 
In the following studies, the induction of BLMH is examined in the context of a potential 
role in MHC I processing (Stolze et al., 2000).  Both heat shock induction and INFg induction 
were evaluated as potential mechanisms for BLMH regulation.  Accumulating evidence suggests 
that BLMH expression is transcriptionally regulated. In skin, BLMH is expressed strongly in the 
epidermis, but weakly or not at all in the underlying dermis or muscle layers (Takeda et al., 
1999; unpublished data).  Increased BLMH expression is observed in some head and neck 
tumors compared to the surrounding normal tissue (Ferrando et al., 1996) and, differential 
activity of the protease is found among tissues such as lung and liver (Lazo and Humphreys, 
1983; Filderman and Lazo, 1991).  In the following experiments, BLMH protein expression was 
not modified by heat shock induction, but was significantly increased by INFg in the principle 
antigen presenting cells of the brain, the microglia. 
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Wild type MEF and HEK 293 cells were subjected to 42° C for 1 h or treated with 10 mM 
MG132, a proteasome inhibitor, for 16 h to evaluate if BLMH can be induced by heat shock or 
proteasome inhibition.  Proteasome inhibition has been shown to result in rapid induction of 
stress protein chaperones (Bush et al., 1997).  Upregulation of the inducible form of heat shock 
protein 70 (hsp 72) was used as a positive control to show induction of cell stress proteins after 
heat shock or proteasome inhibition.  Although induction of hsp 70 was observed in both MEF 
and HEK 293 cells 24 h after a 1 h exposure to heat stress, no changes in the expression of 
BLMH were observed (MEF P = 0.84, 293 P = 0.13 t-test)(Figure 10 A and B).  Proteasome 
inhibition in HEK 293 cells also resulted in significant induction of hsp 70, and a 30 % decrease 
in the expression level of BLMH (P = 0.02) (Figure 10C). 
 
5.2  Results 
5.2.1 Evaluation of Blmh induction by cytosolic stress 
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Figure 10 BLMH protein expression is not altered by heat shock induction. 
MEF or HEK 293 cells were heat stressed by 1 h incubation at 42°C.  After 24 h, cell lysates 
were harvested and immunoblotted for BLMH with rabbit anti-rat Blmh, and HSP 70. (A) MEF 
immunoblot following heat shock induction; Blmh genotype indicated by +/+ for wild type and -
/- for null.  Quantitation to right, data normalized to b  tubulin.  (B) HEK 293 immunoblot 
following heat shock induction; repeat immunoblot with vinculin loading control shown in lower 
panels.  HEK 293 cells were further evaluated for cell stress protein induction by treatment for 
16 h with 10 mM MG132 or vehicle control (DMSO).  Cells were then harvested, lysed and 
proteins were separated by SDS-PAGE and immunoblotted with rabbit anti-rat Blmh, anti-HSP 
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70 and anti-b  tubulin.  Quantitation to the right, data normalized to vinculin.  (C) Immunoblot of 
cell lysates from HEK 293 cells treated with MG132 or vehicle control; repeat immunoblot with 
vinculin loading control shown in lower panels.  Quantitation to the right, data normalized to 
vinculin.  * P < 0.05. 
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INFg induction of the Blmh protein was evaluated in astrocytes and microglia. Rat primary 
astrocyte and microglial cultures were obtained and treated with 300 pg/ml recombinant rat 
INFg.  Cells were harvested 24 h after treatment and assayed by Western blot for levels of Blmh 
protein, b  tubulin and LMP 7 as a positive control.  LMP 7 is induced by INFg as a component of 
the immunoproteasome and serves to indicate activity of the cytokine. Although the levels of 
Blmh were unaltered in the astrocytes (P = 0.20), evidence for induction of Blmh was seen in the 
rat primary microglial cultures (P < 0.005) (Figure 11A, B, D, E).  LMP 7 induction in both 
primary astrocytes and microglial cells indicates active cytokine signaling in both cell lines.  The 
microglial cell line EOC20 was obtained from ATCC and used to verify Blmh induction in 
microglia.   Treatment of EOC20 cells with recombinant INFg resulted in distinct induction of 
murine Blmh approximately 5 fold over 24 h (P < 0.01) (Figure 11 C, F). 
5.2.2 Evaluation of Blmh induction by INFg in primary astrocytes and microglia  
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Figure 11 Blmh is induced in microglia by INFg  
Primary astroglia, primary microglia and EOC20 murine microglial derived cells were either 
treated with recombinant INFg or DMSO as a control and harvested 24 h after treatment.  Cell 
lysates were separated on SDS PAGE, analyzed by Western blot for Blmh, b  tubulin or LMP 7.  
Data shown are representative of 3-9 independent experiments; quantitation grafts represent 
mean + SEM.  A.  Western blot analysis for primary astrocytes.  B. Western blot analysis for 
primary microglia  C.  Western blot analysis for EOC20 microglial cells.  D.  Quatitation of 
astrocyte data, n  = 3.  E.  Quantitation of microglial data, n = 3.  F.  Quantitation of EOC20 data 
n = 3.  For quantitation, Blmh protein band densitometry was normalized to b-tubulin.  *P < 
0.01; ** P < 0.005. 
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 Primary astrocytes and EOC20 cells were treated with INFg and harvested at 0, 24, 48 
and 72 h to determine if the kinetics of Blmh induction differed between the two cell lines. Over 
the time course of the experiment, LMP 7 was clearly induced in approximately ten fold in 
astroglia, but only very weakly induced in the EOC20 microglial cell line.  Furthermore, Blmh 
was not induced over the 72 h time course in astroglia (Figure 12 A and B), but was induced 
nearly 10-20 fold in the microglial derived cells (Figure 13 A and B). 
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Figure 12 INFg treatment does not result in induction of Blmh in astrocytes 
Primary astrocytes were treated with recombinant murine INFg and harvested after 24, 48 or 72 
h.  Cell lysates were separated by SDS PAGE and analyzed by Western blot for Blmh, b  tubulin 
or LMP 7.  A.  Representative Western blot analysis of astrocyte cell lysates.  B.  Quantitation of 
data based on densitometry scan, n = 3; bars represent mean + SEM.  Blmh protein levels are 
unaffected by treatment with INFg. 
B. 
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Figure 13 Blmh induction in EOC20 is time dependent 
EOC20 cells were treated with recombinant murine INFg and harvested after 24, 48 or 72 h.  Cell 
lysates were separated by SDS PAGE and analyzed by Western blot for Blmh, b  tubulin or LMP 
7.  A.  Representative Western blot analysis of EOC20 cell lysates.  B.  Quantitation of data 
based on densitometry scan, n= 6; bars represent mean + SEM. 
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EOC20 cells were treated with 300 pg/ml INFg for 0, 6 or 16 h and then harvested for Western 
blotting to evaluate the early time course of Blmh induction.  Induction of Blmh began to emerge 
as early as 6 h after treatment (Figure 14A).  EOC20 cells were treated for 24 h with INFg after 
which RNA and protein were harvested from parallel cultures and probed by Northern blot or 
Western blot for Blmh respectively. At 24 h, Blmh RNA levels were found to be substantially 
increased following treatment with INFg (Figure 14B).   
5.2.3 Blmh induction by INFg results in increase mRNA  
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Figure 14 Increased Blmh mRNA in response to  INFg  in EOC20 cells 
EOC20 cells were treated with recombinant murine INFg and harvested at the time points 
indicated. Cell lysates were separated by SDS PAGE and analyzed by Western blot for Blmh, b 
tubulin or LMP 7 to determine early induction times.   Induction of Blmh was seen as early as 6 
h after INFg treatment.  A.  Western blot analysis of EOC20 cell lysates.    Total RNA was 
isolated from EOC20 cells before and after INFg treatment and probed by Northern blot for Blmh 
mRNA with a 1365 bp  DIG- labeled double stranded DNA probe. Blmh mRNA was increased 
following INFg treatment B. Northern blot of total RNA isolated from EOC20 cells. 
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EOC20 cells were treated with 50 or 100 pg/ml recombinant murine TNFa alone or in 
combination with 300 pg/ml INFg for 24 h to determine if Blmh is also induced by TNFa.  
Western blot analyses of the cell lysates confirmed prior results with INFg and revealed that 
Blmh was not only induced by TNFa over 24 h, but that it was induced synergistically with INFg 
(Figure 15). 
5.2.4 Evaluation of Blmh induction by TNFa 
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Figure 15 Blmh is induced by TNFa  
EOC20 cells were treated for 24 h with INFg, TNFa or both agents combined (50 pg/ml TNF a 
or 100 pg/ml TNF a).  Cells lysates were separated by SDS PAGE and analyzed by Western 
blotting for Blmh and b  tubulin.  
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Induction of the putative MHC I N-terminal epitope trimming aminopeptidase leucine 
aminopeptidase by INFg has been shown in the human HeLa cell line (Beninga et al., 1998). 
HeLa cells were treated for 24 h with 500 pg/ml human recombinant INFg to determine if 
BLMH was induced in this human cell line.  Cell lysates were assayed by Western blot for 
induction of LMP 7 as a positive control.  No induction of BLMH was observed over 24 h 
following INFg treatment, although strong induction of LMP7 was observe.  These resulta 
suggest a cell type specific function for BLMH in immune surveillence (Figure 16). 
5.2.5 Evaluation of Blmh induction by INFg in the human HeLa cell line 
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Figure 16 BLMH is not induced in HeLa by INFg  
HeLa cells were treated for human recombinant INFg for 24 h and then cell lysates were 
harvested and probed by Western blot for BLMH, b  tubulin or LMP 7.  
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Blmh protein was found to be inducible by INFg in primary rat microglia and the murine 
microglial derived cell line EOC20.  Blmh was also induced by TNFa alone and synergistically 
in combination with INFg in EOC20 cells.  Treatment with INFg also resulted in increased Blmh 
mRNA.  Surprisingly, Blmh was not induced in rat primary astrocytes or in the human HeLa cell 
line although both cell types readily induced the LMP 7 immunoproteasome component.  These 
results suggest a focal immune related function for BLMH that is perhaps limited only to antigen 
presenting cells (APC).  Confirmation of these observations in vivo is important to accertain the 
physiological relevance of the observed cytokine response. Induction of BLMH in other APC 
such as macrophages and dendritic cells has not been tested; however, Blmh has been identified 
as an induced gene head kidney leukocytes from carp treated with Concanavalin A (Yin et al., 
1999). 
INFg is a 45kD homodimeric glycosylated cytokine secreted by thymus derived cells and 
natural killer cells under pathological conditions (Boehm et al., 1997;  Billau et al., 1998).   INFg 
mediates a number of diverse immune related responses including the structural modulation of 
the proteasome, induction of MHC II expression, and induction of expression of adhesion 
molecules such as ICAM 4 from endothelial cells (Boehm et al., 1997; Billau et al., 1998; Fruh 
et al., 1999). The cytokine acts primarily through a ubiquitous receptor and the janus 
kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway (Ramana 
et al., 2002; Kerr et al., 2003).  Synergism between INFg and TNFa is well documented and can 
5.3 Conclusions  
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be mediated in part by cooperation between STAT1 and nuclear factor kB (NFkB)  (Ohmori et 
al., 1997; Paludan et al., 2000;  Wesemann et al., 2003). 
In the normal brain, immune function is quiescent with minimal expression of MHC 
molecules (Havenith et al., 1998;Wekerle et al., 1986).  In addition, the brain parachyma is 
separated from the blood circulation by the blood-brain barrier (Dermietzel, 1975) limiting 
access to most circulating antigen presenting cells.  In early response to injury and infection, 
astrocytes and most notably microglia cells gain the capacity to present antigens via MHC 
molecules.  MHC II antigen presentation is associated with the processing of extracellular 
antigens by proteases in the endolysosomal compartment (Honey and Rudensky, 2003) whereas 
MHC I molecule antigen presentation requires peptides generated by cytosolic proteolysis 
(Kessler et al., 2002).  
Microglia are derived from monomyeloid lineage and function both in support of normal 
neuronal activities as well as possessing immunological competence (Streit et al., 2002).   
Activation of microglia results in conversion from immunologically quiescent to an active 
phagocytic antigen presenting cell with activity that is modulated by inhibitory factors intrinsic 
to the CNS (Dickson et al., 1991; Fontana et al., 1992; Streit et al., 2002).  Although astrocytes 
are not immunologically competent, astrocytes, like microglia, respond to INFg by the 
expression of MHC molecules as well as the production of proinflammatory cytokines such as 
TNFa and IL-1 (Chung et al., 1990; Neuman et al., 2001). 
 The results from this study further support the hypothesis that BLMH has specific 
biological functions in the CNS and that these functions may be related to a role in immune 
surveillance.  In addition, these studies show for the first time, in mammalian cells, regulation of 
the cysteine protease BLMH. 
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The studies presented in this thesis were designed to test the central hypothesis that BLMH has 
unique and important physiological functions in the CNS.  Two different approaches were 
chosen to ask questions regarding the physiological involvement of BLMH in the CNS.  First, 
the immunohistochemical profile of the brains and the behavioral phenotype of mice lacking 
Blmh were compared to wild type controls.  Next, basal transcription of BLMH and potential 
avenues of regulation of BLMH were examined.  The overall conclusions from the data 
presented in the thesis document are consistent with the hypothesis that BLMH has unique and 
important physiological functions in the CNS. 
 Immunohistochemical evaluation of the brains of the aged B6.129 Blmhtm1Geh/J.animals 
showed global astrogliosis in null but not wild type animals.  The presence of astrogliosis is 
suggestive of underlying neuronal injury or dysfunction.  Although the etiology of the 
astrogliosis currently remains unknown, the lack of reactive gliosis characterized by the 
concurrent activation of microglia indicates the abcense of an inflammatory component to the 
pathology.  Activation of astrocytes without microglial activation can occur by paracrine 
signaling from injured neurons through transforming growth factor alpha (Rabchevsky et al., 
1998).  
The behavioral studies examined spontaneous activity (open field test), locomotion and 
balance (rotarod test), pain perception (hot plate test) and learning and memory (contextual fear 
conditioning and water maze).  No differences were observed between null and wild type 
6 DISCUSSION 
6.1 Summary of conclusions 
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animals in the open field testing, but surprisingly, rotarod performance of aged null animals was 
significantly improved over wild type controls.  The reasons for the observed results are 
unknown, but may reflect differences in attributes such as grip strength and balance that become 
more apparent with aging.  Hot plate test results were significantly different between young null 
and wild type animals for front paw lick.  Null animals showed increased latency to front paw 
lick and a trend towards increased latency in other parameters although not statistically 
significant.  The relevance of this finding is unclear. Rotarod and hot plate testing results suggest 
that Blmh null animals may have subtle yet uncharacterized differences in functions relating to 
balance and coordination, and pain perception. 
Young male and female null animals spent significantly less time in the target quadrant 
during water maze probe trials compared to wild type littermates. Although subtle differences in 
sensory function or locomotion cannot be excluded when evaluating these differences, open field 
testing, rotarod testing, visual platform trials during the water maze acquisition phase and water 
maze swim speed assessment ind icate that no overt deficits in sensory or locomotor function 
exist in the null animals. No differences between null and wild type animals performance were 
observed in contextual fear conditioning paradigm, another test of learning and memory. The 
discrepancy between the results from the water maze trials and contextual fear conditioning may 
be due to biological differences underlying learning and memory in these paradigms or could 
reflect the more demanding conditions of the water maze paradigm. 
The underlying reasons for the observed changes in water maze probe trial are unknown, 
but may indicate deficits in learning and memory consistent with a physiological function for 
Blmh in the brain.  Analysis of CNS of the Blmh null mice may be confounded by redundancy in 
function of proteases, effects of flanking genes and unintended consequences on neighboring 
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genes.  Recent strategies for overcoming some of these problems include backcrossing of hybrids 
to address the questions raised by linked genes (Wolfer et al., 2002), the removal of selection 
cassettes by flanking with lox P and conditional knockouts (Brockamp et al., 2002).  The 
proximity of a serotonin transporter gene within 15 kb of human BLMH suggests a systenic 
localization in the mouse.  Although the Blmh targeted deletion appears to have occurred as 
intended, disruption of the serotonin transporter could have obvious unintended consequences in 
the CNS and may merit further investigation.  
Additional CNS characterization of the null animals was hindered by the lack of 
immunhistochemical localization of Blmh.  Although the protein was found distributed 
throughout the CNS by immunoblot, the regional and cellular distribution of the protease in the  
CNS is not known.  Two reports on BLMH immunohistochemistry in human brain suggest that 
protein is primarily neuronal, but those reports lack a definitive positive control (Raina et al., 
1999; Namba et al., 1999).  Attempts at immunohistochemical staining of mouse brains using the 
same antibodies from the published reports failed to reveal any significant signal from the tissue 
of wild type animals.  The data from Blmh immunohistochemistry would permit further detailed 
characterization of the murine CNS.  For example, one could ask if Blmh expression pattern is 
consistent with a role in hippocampal mediated learning and memory or, if regions with 
significant Blmh expression exhibit any neuronal loss or injury in null animals.  Furthermore, the 
cellular distribution of Blmh may also be instructive in better understanding the observed 
astrogliosis. 
The second part of the thesis focused on examination of basal and regulated transcription 
from the BLMH promoter.  Basal transcription was found to be partially mediated by undefined 
elements in the proximal promoter and unaffected by the –134 bp trinucleotide repeat 
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polymorphism.  More importantly, Blmh protein was shown to undergo significant induction in 
response to INFg as well as TNFa in microglial cells.  The Blmh induction by INFg was 
accompanied by increased mRNA.  Surprisingly, Blmh induction was not seen in astrocytes or in 
HeLa cells even though these cells clearly responded to INFg by upregulating LMP7.  These data 
suggest that focal inducible regulation of BLMH in microglial cells is a physiological response 
and further provide support for the notion that BLMH has unique functions in the CNS. 
  
The studies described herein represent only the beginning of an understanding of the 
physiological functions of the cysteine protease BLMH.  The detailed characterization of 
expression pattern of the BLMH in the CNS and in other organs such as lung and skin, where the 
protease is believed to play important roles in normal physiology and disease, is imperative.   
The function of BLMH in the CNS cannot be discussed meaningfully without an understanding 
of the regional and cellular distribution of the protease.   
 In further characterization of the Blmh null mice, the presence of neuronal loss and injury 
should be carefully accessed as the underlying pathology for the observed astrogliosis.   
Additional exploration of the behavioral paradigms may also be fruitful. Assesment of grip 
strength and balance may help clarify the unsual results of the rotarod testing in which aged null 
animals outperformed their littermate counterparts. Results from the water maze paradigm can be 
confounded by subtle sensory and/or motor impairments.  One strategy that has been employed 
to address possible visual impairment is to simplify the visual clues by use of black and white 
patterns (Lamberty and Gower, 1991; Robinson et al., 2001). Extention of the water maze 
6.2 Future directions 
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paradigm to reversal learning using a moving platform format (Chen et al., 2000) or assessment 
of retention by probe trial at longer time intervals following the learning phase may also be 
useful to magnify the small differences in performance already observed.  Evaluation of CA 1 
long term potentiation (LTP), which is an indicator of synaptic plasticity, could provide evidence 
for the decreased water maze probe trial performance being related to cognitive deficits.  If 
BLMH is found to function in MHC class I epitope processing, its function may impact neuronal 
development and plasticity through peptide dependent signaling (Huh et al., 2000).  Evidence for 
BLMH participation in peptide epitope processing in neurons awaits further investigation. 
 Although 5’ untranslated regions of the members of the papain superfamily including 
BLMH lack classical promoter elements, transcriptional regulation may still provide an important 
means of temporal and spatial control for these proteases.  Definition of the BLMH promoter will 
potentially require identification of additional 5’ upstream regions from the 1.2 kb that has been 
cloned.  Classical deletion studies with reporter constructs to determine the location of the 
putative functional promoter elements and gel shift assays to actually identify the transcription 
factors that bind to these elements will also be needed to define the promoter.   
The present history of genetic association studies, particularly with focus on AD, raises 
questions on the usefulness of this type of analysis.  Inconsistencies among these studies may be 
largely attributable to population stratification and heterogeneity (Bertram and Tanzi et al., 2001; 
Emahazion et al., 2001; Finckh, 2003).  If this is indeed the case, then usage of the proper 
controls of disease unrelated SNPs for association studies coupled with linkage disequilibrium 
family and twin studies should allow for correction of the present problems  (Kennedy et al, 
2003).  Genetic factors are believed to play a significant role in pathogenesis of late onset AD 
and at least four additional loci of magnitude similar or greater to apolipoprotein E are proposed 
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to exist (Warwick et al., 2000).  The significance of the genetic association of BLMH with 
AD is unknown; population based molecular genetic studies that are properly controlled and 
aknowledge potential interactions between genes may provide some answers to this question. 
BLMH may function in antigen presentation of MHC I molecules and consequently may 
have an important function in protection against viral infections, tumors, and may play a role in 
peptide mediated MHC I synaptic plasticity and neuronal development (Huh et al., 2000) as well 
as neurodegeneration (Piehl et al., 2001, Weiner and Selkoe, 2002). In AD, inflammation 
appears to contribute to the pathogenesis of the disease as illustrated by adminstration of 
ibuprofen in a transgenic mouse model of AD in which the anti- inflammatory agent resulted in 
significantly less pathology in treated animals compared to controls (Lim et al., 2000).  
Surprisingly, anti- inflammatory agents appear to act in part by altering the processing of APP 
though modulation of the beta-secretase (Sastre et al., 2003).  Epidemiological evidence suggests 
a reduced risk for AD in patients using nonsteroidal anti- inflammatory drugs although 
effectiveness of non-steroidal use in treatment of the disease remains inconclusive (Aisen et al., 
2002).  
Basic characterization of the induction of BLMH by cytokines and its function in 
immune mediated processes should include assessment of BLMH RNA and protein in antigen 
presenting cells including macrophages, dendritic cells and B cells before and after cytokine 
stimulation.  Once the cell populations in which the protease is induced are defined, other 
questions such as the activity profile of BLMH against MHC I aminopeptidase targeted peptides 
and the localization of BLMH can be addressed.  If BLMH is involved in MHC epitope 
processing cytokine induction may result in association of a percentage of the cytoplamic protein 
with components of the MHC I epitope transport system at the ER surface.   An appropriate 
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immunostaining protocol would need to be developed or subcellular fractionation assays utilized 
to assess potential changes in localization.  Although classical signaling pathways for INFg and 
TNFa mediated transcription are known, these pathways remain to be defined for these 
cytokines in BLMH induction.  Finally, many important questions regarding immune function of 
BLMH in microglia in vivo may be effectively addressed utilizing the null mouse model, and in 
fact, several research groups with interest in MHC I epitope processing have requested and 
received breeder pairs for the B6.129Blmhtm1Geh/J animals from our laboratory.  Future research 
on the immune related functions should provide additional understanding of the biological 
functions of this unique cysteine protease and perhaps shed light on its proposed role in 
Alzheimer’s disease.   
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APPENDIX A 
 
 
 
Antibodies 
 
 
Table 6 Antibody list 
 
Antibody Species Epitope Application Dilution 
Rat BLMH Rabbit Unknown WB, IC 1:500 
Human BLMH Chicken Unknown WB 1:500 
HSP70 Rabbit Multiple WB 1:1000 
LMP7 Rabbit Multiple WB 1:1000 
b  tubulin Mouse Single WB 1:2000 
Vinculin Rabbit Multiple WB 1:250 
 
 
WB, Western blot; IC, immunohistochemistry; IP, immunoprecipitation; 
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